

1     **Global Epidemiology and Genetic Environment of *mcr* genes: A One Health Systematic**  
2                                     **Review of Current and Emerging Trends**

3                     Masego Mmatli<sup>a</sup>, Nontombi Marylucy Mbelle<sup>a</sup>, John Osei Sekyere<sup>\*abc</sup>

4     <sup>a</sup>Department of Medical Microbiology, School of Medicine, University of Pretoria, South Africa.

5     <sup>b</sup>Department of Microbiology & Immunology, Indiana University School of Medicine-Northwest,  
6     USA

7     <sup>c</sup>Department of Dermatology, School of Medicine, University of Pretoria, South Africa

8

9     #Address correspondence to Dr. John Osei Sekyere, Department of Medical Microbiology,  
10     School of Medicine, University of Pretoria, 0084 Pretoria, South Africa:  
11     [j.oseisekyere@up.ac.za](mailto:j.oseisekyere@up.ac.za); [joseisek@iu.edu](mailto:joseisek@iu.edu)

12     **Running title:** *Mcr-1*: the dawn of Pandrug resistance.

13     *Tweet: “Within bacteria, mobile colistin resistance genes have spread widely, with a high*  
14     *incidence in human samples. It's critical to comprehend the genetic tools facilitating this*  
15     *spread and their mechanisms of action. These are detailed in this paper, as are new*  
16     *therapeutic strategies for managing these resistance genes.”*

17     **Importance/Highlights**

- 18             • *Mcr* genes are associated with mobile genetic elements that are facilitating its global  
19             dissemination.
- 20             • Using colistin as a growth promoter increases the risk of acquiring *mcr*-positive  
21             *Enterobacteriaceae* in food-producing animals.
- 22             • There is a higher incidence of *mcr* genes in humans than animals.
- 23             • MCR proteins are phosphoethanolamine (PEtN) transferases that mediate the transfer  
24             of PEtN from its primary phosphatidylethanolamine to lipid A.
- 25             • Multiple compounds can synergistically restore colistin’s activity, reducing its dosage  
26             and toxicity.
- 27             • CRISPR-Cas9, endolysins-engineered enzymes, and antimicrobial peptides are  
28             promising therapies for colistin resistance

29

## 30 Abstract

31 **Background:** Mobile colistin resistance (*mcr*) genes modify Lipid A molecules of the  
32 lipopolysaccharide, changing the overall charge of the outer membrane.

33 **Methods:** A systematic review of all studies published between January 2015 to July 2021  
34 was performed. Included articles described *mcr* genes in the context of their genetic  
35 environment, fitness cost, crystal structure, their enzymatic activity and the risk factors  
36 associated with the acquisition of *mcr*. Studies describing the epidemiology of *mcr* genes and  
37 novel therapeutics were included.

38 **Results and Discussion:** Ten *mcr* genes have been described to date within eleven  
39 Enterobacteriaceae species, with *Escherichia coli*, *Klebsiella pneumoniae*, and *Salmonella*  
40 species being the most predominant. They are present worldwide in 72 countries, with human  
41 specimens currently having the highest incidence. This is due to the wide dissemination of  
42 *mcr* in livestock animals, meat, manure, the environment, and wastewater samples, increasing  
43 the risk of transmission via foodborne, zoonotic, and vector-borne routes to humans. The  
44 stability and spread of *mcr* genes were mediated by mobile genetic elements such as the  
45 IncHI<sub>2</sub> conjugative plasmid, which is associated with multiple *mcr*-variants and other  
46 antibiotic resistance genes. The cost of acquiring *mcr* is reduced by compensatory adaptation  
47 mechanisms. MCR proteins are well conserved via structurally. Hence, MCR-1 inhibitors and  
48 therapeutics should be applicable to all MCR proteins.

49 **Conclusion:** *Mcr* genes have spread from animals into the clinical setting, threatening public  
50 health. Combination therapies are a promising option for managing and treating colistin-  
51 resistant *Enterobacteriaceae* isolates whilst reducing the toxic effects of colistin.

52 **Keywords:** colistin resistance; polymyxins; crystal structure; MCR activity; risk factors;  
53 *Enterobacteriaceae*.

## 54 Introduction

55 Colistin was first introduced into clinical practice in the 1950s<sup>1</sup>. It was derived from *Bacillus*  
56 *polymyxa* and belongs to polymyxins<sup>2</sup>, a family of cationic polypeptide antibiotics with  
57 broad-spectrum antimicrobial activity<sup>3</sup>. Colistin has a bactericidal effect on Gram-negative  
58 bacteria and thus is used for treating Gram-negative bacterial infections<sup>1, 2</sup>. Cationic  
59 polypeptides have a high electrostatic attraction to the anionic lipopolysaccharide (LPS)  
60 located on the outer membrane of Gram-negative bacteria. There, it displaces the magnesium

61 and calcium divalent cations ( $Mg^{2+}$  and  $Ca^{2+}$ ), which stabilise the LPS molecules<sup>1, 2</sup>. This  
62 results in the disruption of the cell's permeability, leading to cell death. However, due to the  
63 adverse side effects such as nephrotoxicity and neurotoxicity seen during colistin therapy<sup>2</sup>, in  
64 the early 1980s, it was removed from human use and administered to food-producing animals  
65 as a growth promoter and therapeutics<sup>1, 4</sup>. With the increasing resistance caused by Gram-  
66 negative pathogens such as carbapenem-resistant Enterobacteriaceae that threatens global  
67 public health<sup>5</sup>, colistin was recently reintroduced as a last-line treatment option<sup>3, 4, 6</sup>.

68 Colistin resistance was largely associated with chromosomal-encoded mechanisms that  
69 involved two component systems (TCSs) such as *pmrAB* and *phoPQ*, and mutation(s) in the  
70 *mgrB* regulator in *Klebsiella pneumoniae*<sup>7-9</sup>. These chromosomal mutations mediated colistin  
71 resistance by modifying LPS, changing LPS's overall charge, and reducing the affinity of  
72 polymyxins to the outer membrane<sup>7-9</sup>. The types of modifications seen include the addition  
73 of phosphoethanolamine (PEtN) and 4-amino-4-deoxy-L-arabinose (Ara4N) to the 1-  
74 phosphate or 4-phosphate groups of Lipid A, respectively<sup>10</sup>. The PEtN modification is  
75 associated with the *pmrAB* TCSs and the Ara4N modification with the *phoPQ* TCS alongside  
76 the *mgrB* regulator<sup>10</sup>.

77 Plasmid-mediated colistin resistance (*mcr*) gene was first identified in both animals and  
78 humans by Liu *et al.* (2016)<sup>11</sup> from an *Enterobacteriaceae*. *mcr-1* increased colistin  
79 resistance and encoded a PEtN transferase enzyme that added PEtN to Lipid A<sup>11</sup> at the 4'-  
80 phosphate group<sup>12, 13</sup>. The MCR-1 PEtN transferase enzyme had similar structural properties  
81 to EptC and LptA PEtN transferases from *Campylobacter jejuni* and *Neisseria meningitidis*,  
82 respectively<sup>14, 15</sup>. The lipid A modification is identifiable with a matrix-assisted laser  
83 desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (MS) assay with an  
84 additional  $m/z= 1920.5$  peak observed in *mcr*-producing isolates, representing the modified  
85 Lipid A molecule<sup>16</sup>. This activity is seen across the different *mcr* variants: *mcr-2* to *mcr-10*.

86 After the discovery of *mcr-1*, other novel *mcr* variants i.e., *mcr-2* to *mcr-10*, which are widely  
87 distributed within Enterobacteriaceae, have been reported globally. The identification of the  
88 *mcr-1* gene and its variants, *mcr-2* to *mcr-10*, is largely mediated by PCR screening and  
89 whole genome sequencing (WGS) tools, which are also used in *mcr* surveillance programmes  
90<sup>11, 17-21</sup>. Each *mcr* variant is mostly located on conjugative plasmids, associated with mobile  
91 genetic elements (MGEs), and mediates colistin resistance through PEtN transferase activity.  
92 *mcr* are widely distributed within Enterobacteriaceae, including *Escherichia coli*, *K.*

93 *pneumoniae*, *Salmonella* species, and *Enterobacter* species,<sup>3, 11, 22, 23</sup> and have also been  
94 reported within other Gram-negatives such as *Pseudomonas aeruginosa* and *Acinetobacter*  
95 species<sup>24-26</sup>.

96 Initially, food-producing animals were the reservoir of *mcr* genes due to the high usage of  
97 colistin in livestock<sup>11, 27, 28</sup>. Farmers' consumption of livestock and/or contact with livestock  
98 or their faeces was found to be a risk factor for infection with an *mcr*-producing isolate<sup>28, 29</sup>.  
99 Global screening of *mcr-I* genes in livestock found increased number of *mcr*-producing  
100 isolates, resulting in a ban of colistin in food-producing animals for both growth promotion  
101 and treatment of bacterial infections<sup>30, 31</sup>. The World Health Organisation (WHO), thereafter,  
102 listed colistin as part of the critically important antimicrobials for human medicine. This was  
103 to help preserve the effectiveness of colistin for clinical use and to minimize the transmission  
104 of *mcr* genes from animals, livestock, and the environment to humans<sup>30, 31</sup>.

#### 105 *Purpose of review*

106 This review provides a map of the dissemination of *mcr-I* and its variants. It further evaluates  
107 the genomic content of each *mcr* variant, identifying the possible progenitor and the mobile  
108 elements that each is associated with. We largely look at the *mcr-I* gene, its structure and  
109 function, which enables it to mediate colistin resistance, the fitness cost imposed by *mcr-I*  
110 expression, and the risk factors enabling the dissemination of *mcr* genes. The review further  
111 summarizes the possible treatment options for *mcr*-producing colistin-resistant isolates.

112 Herein, we highlight the epidemiology and evolution of *mcr* genes over the last 6 years by  
113 providing insight into the genomic content of each variant, identifying MGEs that aid in its  
114 dissemination, their global distribution, the crystal structure, and enzymatic activity of MCR  
115 proteins, and promising emerging therapeutics that could manage *mcr*-positive  
116 *Enterobacteriaceae* infections.

#### 117 **Methods**

118 A comprehensive literature search was performed using PubMed. Journal articles published  
119 in English within the last six years (January 2016 to July 2021) were retrieved and screened  
120 using the following keywords: “colistin resistan\*” or “polymyxin resistan\*” and “mcr\*” and  
121 “*Enterobacteriaceae*”. The search was focused on journal articles that discussed the crystal  
122 structure of MCR enzymes and their enzymatic activity, the genetic environment and genetic  
123 support (MGEs) of *mcr* genes, as well as their molecular epidemiology, risk factors and

124 management. However, studies that involved reviews, books and documents, case reports,  
125 case studies were excluded. The inclusion and exclusion protocol used in this review is seen  
126 in Figure 1. The data that was extracted from the included studies is found in Table S1.

## 127 **Results**

### 128 *Characteristics of included studies*

129 The study included 693 articles describing the epidemiology of *mcr* genes, the crystal  
130 structure and enzymatic activity of MCR proteins, the genomic environment of each *mcr*  
131 gene, the risk factors associated with the acquisition of *mcr*-positive *Enterobacteriaceae*  
132 isolates and the novel therapeutic options that can be explored for managing *mcr*-positive  
133 *Enterobacteriaceae*-related infections. A total of 429 articles were included in the  
134 epidemiological data and were used for the statistical analysis. The following data was  
135 extracted from the epidemiology articles: country, study year, specimen type and source,  
136 bacterial species, clone/MLST, *mcr*-type, mobile genetic elements (MGEs) and antibiotic  
137 resistance genes (ARGs) (Table S1).

### 138 *Enterobacteriaceae species distribution*

139 *mcr* genes are well disseminated within Enterobacteriaceae, being frequently identified  
140 within *E. coli*, *K. pneumoniae* and *Salmonella* species, in that order. Other  
141 *Enterobacteriaceae* species that have been identified with *mcr* genes include *Cronobacter*  
142 species, *Citrobacter* species, *Kluyvera* species, *Leclercia* species, *Raoultella ornithinolytica*,  
143 and *Shigella* species (Figure 2A).

144 Initially, *mcr* genes were commonly identified in animals. However, after evaluating the  
145 number of reports collected from 2016 to 2021, the most common source of *mcr*-positive  
146 *Enterobacteriaceae* isolates was human specimens (Figure 2a). In human specimens, *mcr*  
147 genes are frequently isolated from *Enterobacter* sp., *K. pneumoniae*, *Leclercia* sp., and  
148 *Shigella* sp (Figure 2b). *E. coli* is the most common *mcr*-positive isolate and is usually  
149 isolated from animal specimens (Figure 2c); this is also seen with *R. ornithinolytica*,  
150 *Salmonella* sp., and *S. Typhimurium* (Figure 2b). Other sources identified include food and  
151 the environment, which are mostly made up of wastewater samples. In the environment, *mcr*-  
152 positive isolates comprised only three species: *E. coli*, *K. pneumoniae*, and *Kluyvera* sp  
153 (Table S2). Lastly, *mcr*-positive species have been also isolated from food animal and  
154 vegetable samples, being isolated from mostly packaged meat and vegetables. These species

155 include: *Cronobacter* sp., *Enterobacter* sp., *E. coli*, *K. pneumoniae*, *Salmonella*, and *S.*  
156 *Typhimurium*.

157 *Mcr-1* and its variants are the most common and well disseminated of all *mcr* variants  
158 (Figure 3a). This was later shown to be because of multiple factors such as fitness cost and  
159 MGEs. *Mcr-1* has spread globally and has been identified in 69 countries, with *mcr-1* being  
160 the most prevalent *mcr* variant in most countries (Figure 3c). Although the other variants  
161 have spread globally, they have been identified in low numbers compared to *mcr-1* (Figure  
162 3a). This includes *mcr-3*, which has been identified in fifteen countries, with Colombia and  
163 Thailand having the highest counts. *Mcr-3* variants (*mcr-3.1*, *mcr-3.5*, etc) have been  
164 identified in an additional three countries, and in a total of eight countries. This brings the  
165 total count of countries with *mcr-3* genes to eighteen (Table S3, Figure 3c). Other well  
166 disseminated *mcr* variants in low numbers includes *mcr-5* and *mcr-9*, identified in ten  
167 countries. *mcr-8* has been reported in seven countries, *mcr-4* in five countries, *mcr-7* and  
168 *mcr-10* in two countries, and *mcr-6* in Thailand only.

169 Amongst the 70 countries identified with *mcr* genes, countries such as Thailand harboured six  
170 *mcr*-variants (*mcr-1*, *mcr-3*, *mcr-6*, *mcr-7*, *mcr-8* and *mcr-9*) and China harboured eight  
171 variants (*mcr-1*, *mcr-3*, *mcr-4*, *mcr-5*, *mcr-7*, *mcr-8*, *mcr-9* and *mcr-10*). Other countries such  
172 as the USA, Turkey, Spain, Nigeria, Korea, Japan, Italy, France, England, Czech Republic,  
173 Cambodia, Brazil, Belgium, and Bangladesh harboured three to four *mcr*-variants, each  
174 inclusive of the *mcr-1* variants (Figure 3b, Table S3). Most *mcr* genes have been reported in  
175 studies from China (In Figure 3C), which is due to the large volumes of articles being  
176 published on *mcr* epidemiology from China.

177 It has thereafter been seen in China, that clones within *mcr*-positive *E. coli* (MPEC), which  
178 includes ST744, ST410, ST10, ST43, ST101 and ST206, have been identified in all four  
179 sources: food, environment, animals, and humans, seen in Table S4. These clones have,  
180 however, also disseminated globally, where ST744 has been identified in humans in eleven  
181 countries, in food in five countries, in animals in five countries and in the environment only  
182 in China. The MPEC ST10 strain is the most widely distributed within *E. coli*. It has been  
183 identified in animals in seventeen countries, humans in sixteen countries, the environment in  
184 five countries, and in food in five countries. MPEC clones within each country are usually  
185 found in both animals and humans, seen with ST744, ST69, ST117, ST131 and ST354 in  
186 Italy.

187 *S. Typhimurium* is also well distributed globally, with the *S. Typhimurium* ST34 strain  
188 identified in China, Colombia, Denmark, Germany, and the United Kingdom, in both animals  
189 and humans. In China, the *S. Typhimurium* ST34 strain has been identified in both humans  
190 and animals, and in food samples and human specimens in Germany. Similar results are seen  
191 in the monophasic variants of *S. Typhimurium* serovars (S.) 1,4,[5],12:i:-, and *S. 4,[5],12:i:-*,  
192 where ST34 was the only clone identified with *mcr* genes. The *S. 1,4,[5],12:i:-* ST34 strain  
193 has only been identified in Portugal in animals, food and humans, and the *S. 4,[5],12:i:-* has  
194 been identified in Belgium, Canada, Italy, Switzerland and the United States in animals and  
195 humans (Table S4).

196 The direct transmission of *mcr*-positive Enterobacteriaceae (MCRPE) isolates from animals  
197 and humans is discussed in this review (See Risk factors) and the data seen in Table S4  
198 highlights this route of transmission.

#### 199 *Geographical and host distribution of clones and ARGs*

200 Similar to *mcr* genes (Figure 3c), other antimicrobial resistance genes (ARGs) are  
201 predominantly located in China (Figure 4), followed by Germany, Denmark, and England.  
202 Notably, several important ARGs are co-hosted by MCRPE isolates (Figure 3A). This is  
203 expected as colistin is used as a last-line antibiotic for multi-drug resistant (MDR) isolates. A  
204 Table showing the distribution of *mcr*-positive isolates hosting other ARGs is shown in Table  
205 S5.

#### 206 *Plasmid incompatibility groups associated with mcr genes*

207 *Mcr* genes are usually associated with insertion sequences (ISs), which aid in the mobilisation  
208 of resistance genes from the chromosome to plasmids and vice versa<sup>32</sup>. The dissemination of  
209 *mcr* genes is, however, mediated by plasmids, which allow for the horizontal transfer and  
210 spread of resistance genes across different bacterial species, genera, and families<sup>33-35</sup>. *Mcr*  
211 genes have been identified with 41 different plasmid replicons, where eight of these are made  
212 up of IncHI<sub>2</sub> or IncHI<sub>2A</sub>. Most *mcr* variants are associated with multiple incompatibility  
213 groups, with *mcr-1* and its variants being associated with 37 plasmids; IncI<sub>2</sub>, IncX<sub>4</sub> and  
214 IncHI<sub>2</sub> were the most commonly reported (Figure 5). These incompatibility groups have also  
215 been shown to harbour other *mcr* variants: IncI<sub>2</sub> has been associated with *mcr-7*, IncX<sub>4</sub> with  
216 *mcr-2*, and IncHI<sub>2</sub> with *mcr-9*, *mcr-3*, and its variants (Figure 5 and Table S6).

217 Interestingly, the broad-spectrum IncHI<sub>2</sub> plasmid was associated with the most *mcr* variants  
218 and is thus the main driver of *mcr* dissemination across different bacterial species. Further,

219 *mcr-2*, *mcr-6*, and *mcr-7* have only been identified in a single incompatibility group (Figure  
220 5). This is because these *mcr* variants have only been identified in low numbers. A heat map  
221 (Table S4) shows the MGEs profile of the included isolates, which includes both plasmid  
222 groups and IS elements.

## 223 Discussion

224 Since the emergence of *mcr-1* in 2015, it has spread from animals to humans through several  
225 sources and routes, mediated by chromosomal and plasmid borne mobile genetic elements.  
226 The genetic context, associated risk factors, protein structure, and enzymatic activity of each  
227 *mcr* variant are discussed herein.

### 228 *Mcr-1* genomic content

229 The *mcr-1* gene is part of a 2,600 bp cassette that is made up of a putative promoter gene  
230 responsible for the expression of the *mcr-1* gene and the hypothetical protein later identified  
231 as *pap2*<sup>36, 37</sup>. *mcr-1* is speculated to have been derived from *Moraxella* species, which  
232 harbours the intrinsic chromosomal encoded *mcr*-like genes and the *pap2* membrane-  
233 associated lipid phosphatase<sup>37, 38</sup>. The *pap2* gene is found in both *mcr-1* and *mcr-2* cassettes  
234 and shares 41% identity with *Moraxella oloensis* phosphatidic acid phosphatase<sup>20, 39</sup>.  
235 *Moraxella mcr*-like genes with a significant degree of similarity to *mcr-1* and *mcr-2* in *M.*  
236 *porci* and *M. osloensis* were respectively identified in Genbank. Thus, these genes could be  
237 closely related<sup>38</sup>. Poirel *et al.* (2017a) identified an *mcr*-like gene, *mcr-2.2*, from an *M.*  
238 *pluranimalium* strain with an 82% and 99% amino acid identity to *mcr-1* and *mcr-2*,  
239 respectively.

240 An analysis of *mcr-1* sequences deposited in GenBank in 2017 revealed an *mcr-1.10* variant  
241 from *Moraxella* sp. MSGI3-CO3 with 97.61% identity to the plasmid-borne *mcr-1* gene. This  
242 isolate was isolated from the faecal contents of healthy pigs in the United Kingdom in April,  
243 2014<sup>40</sup>. This data suggests that *Moraxella* species may have been the likely source of *mcr-1*  
244 and *mcr-2*<sup>37, 39</sup>. Other evidence that supports the speculation that *mcr-1* evolved from the  
245 *Moraxella* species is the identification of an IS*AplI* element in *M. bovoculi* and *M. porci*<sup>39, 41</sup>.  
246 Li *et al.* (2018) suggest IS*AplI* integrated into *M. bovoculi* and thereafter evolved with the  
247 *mcr*-like genes to the point seen today. This synteny of *mcr-pap2* genes across *Moraxella*  
248 species further highlights this genus as a natural reservoir of *mcr*-like genes and a possible  
249 progenitor due to the high amino acid identity<sup>38, 39, 42</sup>.



250 The mobilization of the *mcr-pap2* unit was thereafter accomplished through IS elements, but  
251 Kieffer *et al.* (2017) identified a replicase gene associated with *mcr-1* on IncX<sub>4</sub> plasmids. The  
252 gene had a 99% identity to *M. lacunata*, thus showing this species as a possible reservoir of  
253 IncX<sub>4</sub> plasmids and further speculating that the *Moraxella* family may encode genetic tools  
254 likely involved in the initial mobilisation of *mcr* genes<sup>38</sup>.

255 Stoesser *et al.* (2016) and Sun *et al.* (2018) suggested that the initial mobilisation of *mcr-1*  
256 genes into Enterobacteriaceae was IS1294-mediated, using a one-ended rolling circle  
257 transposition mechanism shown to be capable of mobilising adjacent sequences. The IS1294  
258 may have mobilised the *mcr-1* cassette into an IS*AplI* composite transposon, creating an  
259 IS*AplI*-*mcr-1*-*pap2*-IS1294-*pap2*-IS*AplI* cassette, which has been identified on *E. coli*  
260 chromosome<sup>32, 43</sup>. It was found that the cassette was still flexible enough to jump from the  
261 chromosome to a plasmid<sup>32</sup> by generating a putative circular intermediate product.

262 There is increasing evidence, however, that the *mcr-1* gene is mobilized primarily as a  
263 composite transposon, Tn6330, that is made up of two copies of IS*AplI* that bracket cassettes  
264<sup>44, 45</sup>. IS*AplI* is an IS that was first described in *Acinetobacillus pleuropneumoniae* and is part  
265 of the IS30 family<sup>46</sup>. The IS elements of this family are flanked by 20-30-base pairs (bp)  
266 inverted repeats (left IR (IRL), right IR (IRR)), which are essential for transposition<sup>47</sup>. The  
267 IR contains a 924 bp open-reading frame that encodes a 44.3 kDa transposase protein  
268 containing a DDE domain, which encodes three conserved amino acid residues viz., D<sub>228</sub>,  
269 D<sub>295</sub>, and E<sub>648</sub> (DDE), as well as carboxylase residues that help coordinate metal ions for  
270 catalysis<sup>44, 47</sup>. Analysis of each IS*AplI* element flanking the *mcr-1*-*pap2* unit found  
271 conserved dinucleotides between the IS*AplI* inverted repeats and the *mcr-1*-*pap2* unit, an AT  
272 dinucleotide on the IRR of the upstream element and CG on the IRL of the downstream  
273 element<sup>44</sup>. An interesting observation in the *mcr-1.10* variant identified in *Moraxella* sp.  
274 MSGI3-CO3 was the presence of these dinucleotides, AT upstream and CG downstream,  
275 flanking the *mcr-1* structure<sup>40</sup>. These dinucleotides were suggested to represent the ancestral  
276 target-site duplications (TSDs) formed during the initial mobilisation of *mcr-1* during IS*AplI*  
277 insertion<sup>40</sup>. Therefore, Snestrud *et al.* (2018) suggested that the formation of the composite  
278 transposon, Tn6330, was through two independent insertion events of IS*AplI* into the TA-  
279 rich region of the *mcr-1*-*pap2* unit, generating the conserved interior 2bp TSDs, AT and CG  
280<sup>44</sup>. Subsequent transposition of the Tn6330 would therefore generate new TSDs at the new  
281 target site but would retain both internal conserved 2bp dinucleotides<sup>40</sup>.

282 As stated above, the IS*ApII* is part of the IS30 family. The family has been shown to  
283 mobilize through a copy (out) and paste mechanism, forming circular intermediates of a  
284 single IS during transposition. The family is further known to have a high affinity for certain  
285 target sites resembling their IR sequence<sup>46-48</sup>. Multiple studies have investigated the  
286 mechanisms of IS*ApII* in mobilising the *mcr-I* gene and found that during each transposition  
287 event, the transposon was a circular intermediate covalently closed doubled stranded DNA,  
288 5 699 bp in size and generated a 2 bp direct repeats at the insertion site which was an AT-rich  
289 region<sup>37, 44, 47, 49</sup>, a similar mechanism seen in the IS30 family. IS*ApII* is most likely an  
290 important factor responsible for the insertion and fixation of the *mcr-I* gene into various  
291 classes of self-transmissible plasmids and host chromosomes<sup>37, 41, 50</sup>. The formation of an  
292 intermediate structure consisting of IS*ApII* and *mcr-I* during mobilization indicates that the  
293 resistance genes have become highly mobilizable in both plasmids and the chromosomes<sup>41</sup>.  
294 After the first identification of *mcr-I* in pHNSHP45<sup>11</sup>, an IncI<sub>2</sub> plasmid, *mcr-I* was thereafter  
295 detected in a wide range of conjugative plasmids, IncI<sub>2</sub>, IncHI<sub>2</sub>, IncX<sub>4</sub>, IncF, and IncP with  
296 the potential to mediate the dissemination of *mcr-I* genes into other Gram-negative bacteria  
297<sup>50</sup>. Petrillo *et al.* (2016) suggest that the insertion of the complete transposon triggers the  
298 rapid mobilization of conjugative plasmids, encouraging their dissemination across the  
299 *Enterobacteriaceae* family<sup>51</sup>. The copy out and paste in mechanisms allow for the  
300 transposition of the *mcr-I* cassette, and the decay properties of IS*ApII* further transfix the  
301 resistance gene into a plasmid or chromosome<sup>49, 52</sup>.

302 Snesrud *et al.* (2017) and Li *et al.* (2019) discovered that IS*ApII* is highly active and that a  
303 single copy of IS*ApII* can mobilize independently of *mcr-I* across the host genome in AT  
304 regions with a slight central GC bias<sup>49, 53</sup>. A sequencing analysis of four *mcr-I* containing  
305 isolates performed by Snesrud *et al.* (2017) identified two to six copies of IS*ApII* element  
306 throughout the isolates' genome. The highly active nature of the IS*ApII* elements thereafter  
307 triggers the deletion of the flanking IS*ApII* copies to prevent further plasmid rearrangements  
308<sup>40, 49</sup>. Snesrud *et al.* (2016) analysis of the *mcr-I* sequence environment showed that Tn6330  
309 has a strong tendency to decay through deletion, removing parts of, or both copies of IS*ApII*,  
310 thus transfixing *mcr-I* into a vector plasmid. This has led to the observation of many  
311 sequences lacking one or both of IS*ApII*<sup>37, 44</sup>. Composite transposons in the IS30 family have  
312 been shown to contribute to replicon stabilization through transposition and illegitimate  
313 recombination<sup>44, 47</sup>. The loss of IS*ApII* elements results in the loss of transposability,  
314 stabilizing the *mcr-I* cassette in plasmids, which facilitates the widespread dissemination of

315 the colistin resistance gene in self-transmissible plasmids<sup>44, 54, 55</sup>. As discussed, *ISApII* has a  
316 significant bias for insertion in AT-regions and generates TSD of two or three bases. The  
317 analysis of the *mcr-I* cassette in the absence of *ISApII* elements has shown that the cassette is  
318 found in similar locations as per plasmid type and flanked by conserved trinucleotides (5'-  
319 ATA-3') that are found immediately downstream of the *ISApII* IRR<sup>44, 56</sup>. This is because the  
320 deletion event involves 1-4 flanking nucleotides that remain at the deletion junction<sup>40</sup>.

321 An analysis of *mcr-I* sequences deposited in the public database has shown four general  
322 structures of *mcr-I* sequences: the complete composite transposon with both copies of *ISApII*  
323 elements; structures with a single copy of *ISApII* located downstream of *mcr-I*; structures  
324 that lost both copies and a rare fourth structure with a single copy of *ISApII* located upstream  
325<sup>40, 44</sup>. In structures with a single copy of *ISApII* found upstream and the IRR sequence of the  
326 downstream of deleted *ISApII*, Snesrud *et al.* (2016) suggest that the transposase encoded by  
327 the upstream *ISApII* can recognize the downstream IRR and thereafter still be able to  
328 mobilize the bracketed region without a complete composite transposon<sup>44</sup>. The partially or  
329 complete removal of *ISApII* was through an illegitimate recombination that generated  
330 mismatches and deletions. Sun *et al.* (2018) found that the 3' end of the *mcr* cassette unit was  
331 flexible in all IncX<sub>4</sub> plasmids and the sequence could match with the perfect IRR of *ISApII*,  
332 though all IncX<sub>4</sub> currently lack *ISApII* elements. The evidence from this study suggests that  
333 the TSD generated, and the six mismatches acquired through illegitimate recombination  
334 could be identified as a "relic" to track an insertion event that resulted in the subsequent loss  
335 of *ISApII*<sup>32</sup>. The loss of *ISApII* elements in IncX<sub>4</sub> was conducive to maintaining the *mcr-I*  
336 cassette on the plasmid<sup>32</sup>, increasing its stability, and thus allowing for the dissemination of  
337 resistance genes via the plasmids<sup>44, 54, 55</sup>. The identification of these IRR in IncX<sub>4</sub> plasmids  
338 allows for the conclusion that *ISApII* was associated with the transposition of the *mcr-I*  
339 cassette into IncX<sub>4</sub> plasmids<sup>57</sup>.

#### 340 *Fitness cost of mcr-I genes on bacterial host*

341 The acquisition of *mcr-I* bearing plasmids has been shown to have a beneficial effect on the  
342 host, improving bacterial survival in the presence of colistin treatment<sup>58</sup>. The acquisition and  
343 expression of the *mcr-I* gene results in the incorporation of *MCR-I* into the bacterial  
344 membrane and the phosphoethanolamine (PEtN) modification of the lipopolysaccharides  
345 (LPS)<sup>59</sup>. However, multiple studies have shown that the expression of *mcr-I* imposes a  
346 fitness cost by placing an energy burden on the host<sup>60</sup>, impairing cell growth, and  
347 diminishing bacterial fitness<sup>59</sup>. Andersson *et al.* (2006)<sup>61</sup> explained that a significant fitness

348 cost is seen when the susceptible strain outcompetes the resistant strain in an antibiotic free  
349 environment. The imposed fitness cost of a conjugative plasmid harbouring a resistance gene  
350 has been shown to be because of various factors such as the resistance mechanisms, the  
351 bacterial species, and the antibiotic<sup>58</sup>.

352 Evaluating the cost of colistin resistance on resistant strains, it is shown that certain  
353 chromosomal mutations within genes such as *mgrB* have no significant fitness cost on *K.*  
354 *pneumoniae*<sup>62</sup> whilst genes such as *pmrB*, do<sup>63</sup>. Giordano *et al.* (2019)<sup>63</sup> found that the  
355 expression of the *mcr-1* gene imposes less of a burden on *K. pneumoniae* than the mutated  
356 *pmrB* gene. The chromosomal mutations within *pmrAB*, *crab*, *phoPQ*, and *mgrB* genes have  
357 been shown to mediate colistin resistance through the phosphorylation of lipid A<sup>64-66</sup>.  
358 Tietgen *et al.* (2018) discovered that the fitness costs imposed by *mcr-1* plasmid carriage,  
359 such as growth rates and cytotoxicity, could be species-specific<sup>67</sup>. Particularly, the  
360 acquisition of an *mcr-1*-harbouring plasmid in *K. pneumoniae* has been shown to impose a  
361 significant fitness cost on the host<sup>58</sup>, but multiple studies have shown that the acquisition of  
362 an IncI<sub>2</sub> plasmid, in various sizes, carrying *mcr-1* had no significant cost on the host<sup>68, 69</sup>.  
363 This may be plasmid and/or species specific or may be due to acquired compensatory  
364 mutations within the IncI<sub>2</sub> plasmid. However, the overexpression of *mcr-1* was seen to result  
365 in profound changes in the architecture of the outer membrane, resulting in the loss of  
366 membrane structural integrity and causing leakage of cellular cytoplasm, resulting in cell  
367 death<sup>59, 70</sup>.

368 Yang *et al.* (2017a)<sup>59, 70</sup> found that the overexpression of *mcr-1* imposes a significant cost by  
369 decreasing the growth rate, causing significant membrane degradation and moderate fitness  
370 loss. They came to this conclusion through evaluating the effects of *mcr-1* expression on the  
371 relative fitness of *E. coli* TOP10 and found that with increasing levels of *mcr-1* expression  
372 resulted in a significant fitness burden on the host<sup>59, 70</sup>. An analysis of the cellular  
373 morphology in the *mcr-1* overexpressed strains using a transmission electron microscopy  
374 showed cell architecture alterations and a complete loss of cellular morphology. The  
375 overexpression of *mcr-1* altered the structural integrity of the outer membrane and further  
376 impaired the cell membrane<sup>59</sup>. They finally found that the embedding of *MCR-1* into the  
377 outer membrane and the PEtN modifications of Lipid A were the leading factors contributing  
378 to fitness cost and membrane degradation. Therefore, the expression of *mcr-1* in host strains  
379 is tightly controlled to regulate the *mcr-1* fitness cost<sup>70</sup>.

380 *Mcr-I* expression is therefore quite toxic for the bacterial host, and the acquisition of a *mcr-I*-  
381 bearing plasmid thereafter results in compensatory adaptation that allows for the maintenance  
382 of high-cost conjugative plasmids<sup>19, 71, 72</sup>. Dahlberg *et al.* (2003)<sup>72</sup> found that the cost of  
383 plasmid carriage is reduced over long-term culture because of compensatory mutations. The  
384 host chromosome or plasmid evolves compensatory mutations that, in the case of plasmids,  
385 enhance the fitness of the host, and in the case of chromosomal mutations, aid the host in  
386 evolving towards new growth conditions by decreasing the plasmid carriage cost<sup>72</sup>. This has  
387 been seen in multiple studies where *mcr-I* bearing plasmids initially imposed a biological  
388 cost on the transformant. However, overtime, the cost of plasmid carriage in long-term  
389 cultures was largely compensated for and plasmids were stably maintained through passages  
390<sup>59, 63, 67, 71, 73</sup>.

391 Ma *et al.* (2018a)<sup>71</sup> investigated the potential mechanisms involved in compensatory  
392 adaptation through comparative genomics and identified single nucleotide polymorphisms in  
393 several genes. Amongst the genes identified in this study are *dnaK*, which encodes a  
394 molecular chaperon involved in chromosomal DNA replication, and *cpoB*, which encodes an  
395 RHS repeat protein involved in maintaining the cell envelope integrity during cellular  
396 division<sup>71</sup>. These two genes are located on the chromosome and have non-synonymous  
397 single nucleotide polymorphisms (SNPs). The role of these genes in reducing plasmid  
398 carriage cost is unknown and may represent novel mechanisms. The study further shows that  
399 bacteria may use different strategies to reduce the fitness cost of plasmid carriage under  
400 different environmental conditions<sup>71</sup>.

401 In the absence of antibiotics (colistin) selective pressure, *mcr-I* bearing plasmids have been  
402 shown to be less maintained and that the complete elimination of the *mcr-I* gene within a  
403 population is possible<sup>58</sup>. Nang *et al.* (2018)<sup>58</sup> performed a plasmid stability assay and found  
404 that in the absence of colistin, there was a gradual loss of the *mcr-I* plasmid, there was a  
405 decrease in its maintenance within the population. This may be due to the instability of *mcr-I*  
406 harbouring plasmids<sup>58</sup>. Arcilla *et al.* (2016) have shown the complete elimination of *mcr-I*  
407 bearing bacteria in travellers returning to their home country after a month<sup>74</sup>.

#### 408 *MCR-I structure*

409 *MCR-I* is a 541 amino acid, integral membrane protein made up of two domains: a C-  
410 terminal periplasmic catalytic domain and an N-terminal 5'-helix transmembrane domain<sup>75</sup>,  
411<sup>76</sup>. The transmembrane (TM) domain is made up of 5-membrane spanning  $\alpha$ -helices with an

412 overall positive charge because of positively charged residues, which interact with the  
413 negatively charged phospholipid head groups of the membrane bilayer. The TM domain  
414 anchors the protein into the inner membrane and is connected to the catalytic domain through  
415 a bridging helix<sup>75</sup>. The catalytic domain is made up of both positively and negatively charged  
416 residues, where the negatively charged residues create the binding pockets and allow them to  
417 be buried within the domain<sup>75</sup>.

418 The overall shape of *MCR-1* is a hemispherical shape composed of several  $\beta$ - $\alpha$ - $\beta$ - $\alpha$  motifs  
419 made up of  $\beta$ -strands sandwiched between  $\alpha$ -helical structures<sup>12, 77</sup>. The catalytic domain has  
420 an alkaline phosphatase family  $\alpha/\beta/\alpha$  fold, also with a hemispheric shape equipped with a  
421 zinc binding pocket containing a conserved phosphothreonine-285 residue (Figure 6)<sup>12, 77</sup>.  
422 The pocket is common to PEtN transferases and alkaline phosphatase; each enzyme,  
423 however, differs in the orientation and number of zinc molecules<sup>77</sup>. The pocket is proposed  
424 to be critical for the nucleophilic attack of the phosphate of the donor PE substrate by  
425 stabilizing the alkoxide of the Thr285<sup>77</sup>. The Thr285 residue, is the catalytic nucleophile that  
426 acts as both a nucleophile and a PEtN acceptor during the catalytic mechanisms. The residue  
427 is critical to *MCR-1*'s function as mutations to this residue significantly decrease MCR-1's  
428 activity<sup>77, 78</sup>. The catalytic domain of MCR-1 is further made up of six cysteine residues that  
429 form three disulphide bonds, Cys281/Cys291, Cys356/Cys364 and Cys414/Cys422<sup>77</sup> that  
430 stabilize and anchor the  $\beta$ - $\alpha$ - $\beta$ - $\alpha$  motifs<sup>12</sup>. These disulphide bonds are conserved, and  
431 equivalents are present in both LptA and EptC transferases<sup>77</sup>, although LptA has four more  
432 cysteine residues.

433 The zinc binding pocket is in the active site of MCR-1 and is made up of conserved residues  
434 viz., Asp465, Glu246, His466, His395, and Thr285, and is made up of zinc molecules (Figure  
435 6b)<sup>77, 79</sup>. The conserved residues are critical for the substrate binding of MCR-1<sup>79</sup> and  
436 mutations in these amino acids abolish the MCR-1 activity, lowering the colistin MIC value  
437 down to control levels<sup>13</sup>. The five conserved residues are well conserved in *MCR-1*, LptA,  
438 EptC and other alkaline phosphatase family members, although the nucleophile residue may  
439 differ between enzymes<sup>78</sup>. MCR-1 has three zinc molecules clustered around the active site:  
440 Zn1 is buried within the active site and co-ordinated by the phosphate oxygen of Thr285; it is  
441 conserved in LptA and EptC<sup>77</sup>. Zn2 is co-ordinated by His395, bound to a phosphate oxygen  
442 of Thr285 and three water molecules, forming a trigonal bipyramidal configuration seen in  
443 Figure 6b<sup>77</sup>. Hu *et al.* (2016a) found that Zn2 is not critical for maintaining MCR-1 activity.

444 This may be because it is located on the surface of the active site. A structural comparison  
445 between LptA, EptC and MCR-1 found that the Zn2 site is less conserved. Hence, Hinchliffe  
446 *et al.* (2017)<sup>78</sup> concluded that an intact Zn2 site was not a prerequisite for MCR-1's catalytic  
447 activity. However, His395 residue is important for the structure and activity of MCR-1. The  
448 Zn3 molecule, unlike the other zinc molecules, is not co-ordinated by the conserved residues  
449 but is tetrahedrally co-ordinated by four water molecules. The seven water molecules found  
450 in the active site, co-ordinating Zn2 and Zn3, are embedded in the protein through hydrogen  
451 bonding<sup>77</sup>. The catalytic domain is thus a zinc-rich area (Fig. 6b), suggesting that MCR-1  
452 may be able to attract zinc ions at different levels into the domain<sup>13</sup>. The role of zinc in  
453 mediating lipid A modification, the catalytic mechanism, was evaluated by measuring the  
454 colistin MIC in the presence and absence of EDTA. Hinchliffe *et al.* (2017)<sup>78</sup> found clear  
455 reductions in colistin MIC values after EDTA treatment and concluded that the presence of  
456 zinc in the active site was important for MCR-1 function.

457 MCR-1 mediates the transfer of PEtN from the primary phosphatidylethanolamine (PE) to  
458 lipid A moiety at the 4'-phosphate group<sup>13, 79</sup>. Wei *et al.* (2018)<sup>75</sup> and Liu *et al.* (2018)<sup>76</sup>  
459 investigated the molecular mechanism involved in this process. Wei *et al.* (2018) identified  
460 that the active site within the catalytic domain is made up of two binding pockets: the PEtN  
461 binding pocket and the Lipid A binding pocket. These binding pockets are in close proximity  
462 and are integrated within each other<sup>75</sup>. Wei *et al.* (2018)<sup>75</sup> observed that ethanolamine was a  
463 good analogue of PEtN and D-glucose for lipid A. Ethanolamine (ETA) is a good analogue as  
464 it mimics the covalent PEtN-enzyme intermediate. Lipid A is made up of two glucosamine  
465 units that are attached to acyl chains. Thus, monosaccharides and disaccharides can mimic a  
466 Lipid A molecule as they are both hexacyclic compounds<sup>75, 76</sup>.

467 The PEtN binding pocket that accommodates ETA is made up of Glu246, Thr285, Asn329,  
468 Lys333, His395, Asp465, His466 and His478 residues<sup>75</sup>. This pocket is responsible for the  
469 binding of phosphatidyl-ethanolamine (PE), which is stabilized through hydrogen bonding  
470 with Asn329, a water molecule, and phosphorylated Thr285<sup>75</sup>. Analysis of the entry of ETA  
471 into the pocket showed that the pocket undergoes conformational changes to adjust to the  
472 substrate. These included a 50° rotation of the His395, accomplished by breaking a hydrogen  
473 bond with a water molecule (wat7) and creating a new hydrogen bond with a new water  
474 molecule (wat8)<sup>75</sup>. This releases the wat7 molecule from the PEtN binding pocket and thus,  
475 collectively, the conformational changes create room to accommodate the substrate, ETA.  
476 The entry of ETA further deprotonates the phosphorylated Thr285 residue, forming a PEtN

477 molecule and a nucleophilic state at Thr285<sup>75</sup>. The Zn1 molecule subsequently facilitates the  
478 stabilization of the nucleophilic state of Thr285 that allows that residue to thereafter attack  
479 the PEtN, creating a PEtN enzyme intermediate. This constitutes the first step of the MCR-1-  
480 mediated catalytic process<sup>75</sup>.

481 Wei *et al.* (2018)<sup>75</sup> and Liu *et al.* (2018)<sup>76</sup> investigated the mechanisms behind PEtN-  
482 transfer reaction with a lipid A analogue, D-glucose, identified within the Lipid A binding  
483 pocket. This pocket is made up of the following residues: Thr283, Ser284, Tyr287, Pro481  
484 and Asn482, that is located near the Thr285 residue (Figure 7). The analysis of D-glucose  
485 found that D-glucose was held in the pocket by Thr285, Ser284 and Asn482 and was flanked  
486 by Tyr281 and Pro481 forming a sandwich structure of a  $\pi$ - $\pi$  conjugative interaction<sup>75, 76</sup>. The  
487 importance of the residues in both PEtN and Lipid A binding pockets in MCR-1 activity were  
488 evaluated through mutation construction. Mutations within Thr285, Asn329, Lys333, Glu246,  
489 His398, Asp465, His466 and His478 of the PEtN binding pocket and Tyr281 and Pro481 of  
490 the Lipid A binding pocket, resulted in a decrease in colistin MIC values<sup>75</sup>. However, these  
491 mutations did not disrupt the protein expression and membrane localization of the MCR-1  
492 protein. The mutations of Tyr281 and Pro481 in the lipid A binding pocket highlights the  
493 importance of this pocket in the MCR-1 activity. Wei *et al.* (2018)<sup>75</sup> suggests that it could  
494 bind to the glucosamine group of Lipid A and allows for the transfer of the reactive  
495 phosphate group from PEtN enzyme intermediate to lipid A. Thus, the second step of the  
496 catalytic process therefore involves the transfer of PEtN to Lipid A that is situated in a nearby  
497 pocket<sup>75</sup>.

498 The MCR-1 catalytic domain is therefore made up of a PEtN binding pocket and a Lipid A  
499 binding pocket that mediate the transfer of PEtN from the PEtN binding pocket to lipid A  
500 moiety at the 4'-phosphate group<sup>13, 79</sup>. This activity is validated through MALDI-TOF mass  
501 spectrometry (MS), provides *in-vivo* evidence of the MCR-1 activity<sup>79, 80</sup>. This is  
502 accomplished by evaluating the LPS lipid A MS profile in the presence and absence of *mcr-I*  
503 expression as adding PEtN increases Lipid A mass units (+123)<sup>79, 81, 82</sup>. In the absence of  
504 *mcr-I* expression, there is a single Lipid A peak ( $m/z = 1797.4$ ) and in the presence of *mcr-I*  
505 expression, there are two unique peaks. The first peak is the wildtype bis-phosphorylated,  
506 hexa-acylated lipid A ( $m/z = 1797.4$ ) and the second peak is the PPEtN-4' ( $m/z = 1920.5$ )<sup>81</sup>.

507 *MCR-I* has thus proven to have PEtN transferase activity and has a sequence and structural  
508 similarity to EptC and LptA PEtN transferases in *Campylobacter jejuni*<sup>14</sup> and *Neisseria*  
509 *meningitidis*<sup>83</sup>, respectively<sup>77-79</sup>. The active sites of the three PEtN transferases are highly



510 conserved, i.e., the phosphorylated catalytic nucleophile Thr285, disulphide bonds, zinc  
511 binding pockets and the conserved active site residues<sup>78</sup>. Therefore, these three sites are  
512 important for MCR-1 function; these conserved mechanistic activities and binding pockets  
513 will allow for the use of MCR-1 inhibitors to also inhibit chromosomally encoded PEtN  
514 transferases, restoring colistin susceptibility in acquired and intrinsically resistant bacteria<sup>77</sup>.

#### 515 *Mcr-2 variant*

516 *Mcr-2* was first identified in ten *E. coli* isolates during a passive surveillance screening of  
517 diarrhoea in calves and piglets, and like *mcr-1*, *mcr-2* was located on a conjugative plasmid  
518 (IncX<sub>4</sub>) and was able to confer clinical colistin resistance (4-8 mg/L)<sup>20</sup>. The gene was  
519 identified due to the presence of a putative membrane protein identified as a PEtN transferase  
520 in *mcr-1* negative isolates<sup>20</sup>. This variant has a 76.75% and 80.65 % nucleotide sequence and  
521 amino acid identity, respectively, to *mcr-1*<sup>20</sup>. *mcr-2* encodes a 538 amino acid polypeptide  
522 consisting of two domains: a C-terminal periplasmic catalytic domain and an N-terminal 5'-  
523 helix transmembrane domain<sup>20, 33</sup>. Sun *et al.* (2017b) found that the acquisition of the  
524 transmembrane domain allows for the correct localization of PEtN transferases within the  
525 periplasm and that the deletion of this domain impairs MCR-2's ability to confer colistin  
526 resistance.

527 A genetic analysis of the IncX<sub>4</sub> plasmid found that *mcr-2* was located within two IS1595-like  
528 ISs and a 279 bp open reading frame (ORF), located downstream the *mcr-2* gene<sup>20</sup>. The ORF  
529 encodes a PAP2 membrane-associated lipid phosphatase which is related to the PAP2 protein  
530 encoded by the ORF of *mcr-1*<sup>20, 84</sup>. The ORF of *mcr-2* has a 41% identity to the phosphatidic  
531 acid phosphatase encoded by *M. osloensis*. When Xavier *et al.* (2016) removed the *mcr-2*-  
532 pap2 from the IS1595 backbone, a BLASTn search produced a single hit to *M. bovoculi*  
533 strain with a 75% identity across a 100% query coverage. To support the hypothesis that the  
534 *mcr-2* cassette originated from *Moraxella* sp., a phylogenetic analysis of the MCR-2 protein  
535 was performed and found that the protein was a distinct protein from *MCR-1* and might have  
536 evolved from *M. catarrhalis*<sup>20</sup>. Sun *et al.* (2017b) suggests that the emergence of the PEtN  
537 transferases, *MCR-1*, *MCR-2* and *Neisseria* LptA was a parallel evolutionary event for  
538 functional acquisition of colistin resistance during some environmental selection pressure,  
539 i.e., the intensive use of colistin in animal feed<sup>33</sup>.

540 IS1595 is composed of a transposase gene flanked by two inverted repeats (18 bp each). *Mcr-*  
541 *2* is thus present within a complete transposon which allows for horizontal gene transfer<sup>33</sup>.

542 Sun *et al.* (2017b) found that the *IS1595* composite transposon was able to form circularized  
543 intermediates, which were identified during an inverse PCR assay. Hence, the *IS1595*  
544 elements are involved in the mobilisation of the *mcr-2* cassette via homologous  
545 recombination events, which like *mcr-1*, allows for the dissemination of the resistance gene  
546 across diversified bacterial hosts<sup>33</sup>.

547 After the first identification of *mcr-2* in Belgium on an IncX<sub>4</sub> plasmid, an effective vehicle  
548 for dissemination of resistance and virulence genes with a high transfer frequency<sup>20, 33</sup>, it was  
549 thereafter identified in *Salmonella* sp. on IncX<sub>4</sub> plasmids in Belgium in 2018 from retail meat  
550 collected in 2012<sup>85</sup>. It has subsequently been found in pig and poultry samples in 19  
551 provinces in China, where the prevalence of *mcr-2* in the study was 56.3% in poultry<sup>86</sup>. *Mcr-*  
552 *2* was then found in clinical settings in Iran, in stool samples collected between 2011-2016<sup>87</sup>.  
553 In Egypt, *mcr-2* was widespread and identified in humans, wild birds, and the environment  
554 (water sources)<sup>88</sup>. Compared to *mcr-1*, *mcr-2* has not spread across the world and imposed a  
555 big threat to public health though found on a low fitness burden plasmid. The gene has  
556 however spread well within the *Enterobacteriaceae* family i.e., *E. coli*, *K. oxytoca*, *K.*  
557 *pneumoniae* and *Salmonella* sp.

#### 558 *The mcr-2.2 variant: mcr-6*

559 AbuOun *et al.* (2017)<sup>42</sup> identified an *mcr-2.2* variant in *Moraxella pluranimalium* strain  
560 isolated from a pig in Great Britain. The MCR-2.2 protein was found to have an 87.9% amino  
561 acid identity to MCR-2, encoding 65 amino acid substitutions<sup>42</sup>. Partridge *et al.* (2018)<sup>89</sup>  
562 suggested that since *mcr-2.2* encodes a protein that is 87.9% identical to the original MCR-2,  
563 it should be labelled as *mcr-6*. The *mcr-6* gene like *mcr-1* and *mcr-2* was associated with the  
564 PAP2 gene located downstream of *mcr-6*<sup>42</sup>. The *mcr-6* has only been identified in the *M.*  
565 *pluranimalium* MSG47-C17 strain isolated in 2012 and has not disseminated into the  
566 *Enterobacteriaceae* family. AbuOun *et al.* (2017)<sup>42</sup> however highlights that *Moraxella*  
567 species could have been the source of *mcr-pap2* genes.

#### 568 *Mcr-3 variant*

569 The first identification of *mcr-3* was in *E. coli* isolated from pigs in China<sup>90</sup>. The identified  
570 1626 bp putative PETN transferase has a 45.0% and 47.0% nucleotide sequence identity to  
571 *mcr-1* and *mcr-2* and an amino acid sequence identity of 32.5% and 31.7%, respectively<sup>90</sup>.  
572 Using RaptorX, Yin *et al.* (2017)<sup>90</sup> predicted that MCR-3 protein, like MCR-1, and MCR-2,  
573 is made up of two Domains, domain 1 containing a five-transmembrane helix and domain 2

574 containing the periplasmic domain made up of the putative catalytic centre<sup>90</sup>. Despite the  
575 difference between *mcr-3* and the other *mcr* genes, Kieffer *et al.* (2018)<sup>91</sup> found that an *mcr*-  
576 3.12 variant had the same PEtN transferase activity and the expression of *mcr-3* resulted in an  
577 8-fold increase in MIC value of colistin<sup>92</sup>. An LPS analysis showed that both MCR-1 and  
578 MCR-3 produced an identical additional peak at *m/z* 1921 in *mcr-1* and *mcr-3* positive *E.*  
579 *coli*. Thus, the differences in nucleotide or amino acid sequences between the two *mcr* genes  
580 had no impact on the PEtN activity<sup>91,93</sup> and proving that MCR-3 confers colistin resistance in  
581 the same manner as MCR-1 and MCR-2<sup>91</sup>.

582 To further elaborate this observation, the expression of *mcr-3* has been shown to significantly  
583 impair the cell wall integrity and decrease the electron density of *mcr-3* producing *E. coli*<sup>94</sup>, a  
584 characteristic that has been previously described in *mcr-1* producing isolates<sup>67,70,94</sup>. Yang *et al.*  
585 *al.* (2020)<sup>94</sup> further evaluated the fitness cost imposed by *mcr-3* expression and compared it  
586 to that of *mcr-1* and found that the expression of both *mcr* genes had an impact on the  
587 bacterial fitness; however, the *mcr-3.1* and *mcr-3.5* imposed lesser fitness costs.

588 *Mcr-3* genetic context is made up of a diacylglycerol kinase (*dgkA*) gene located downstream  
589 the *mcr-3* gene and is thereafter flanked by a truncated ( $\Delta$ ) *ISKpn40* upstream and an intact  
590 *ISKpn40* downstream<sup>52</sup>. In some cases, a  $\Delta$ TnAs2 element is located upstream of the  
591  $\Delta$ *ISKpn40* element<sup>52, 90, 95</sup>, and the genetic context ( $\Delta$ TnAs2- $\Delta$ *ISKpn40-mcr-3-dgkA*-  
592 *ISKpn40*) is flanked by an IS26 element upstream and an intact *IS15DI* element  
593 downstream<sup>96 34, 52</sup>. These elements, *ISKpn40*, TnAs2, IS26 and *IS15DI* were identified and  
594 hypothesised to play a role in the transposition of the *mcr-3* cassette among different species  
595 or bacterial genera<sup>35, 52, 97</sup>. Sia *et al.* (2020)<sup>52</sup> identified two circular intermediates of 3535 bp  
596 and 5990 bp made up of *mcr-3-dgkA-ISKpn40* and IS $\Delta$ 26-TnAs2- $\Delta$ *ISKpn40-mcr-3-dgkA*-  
597 *ISKpn40*, respectively, during conjugation experiments. Wang *et al.* (2018)<sup>35</sup> evaluated the  
598 transferability of the 5990 bp circular intermediate and concluded that the  $\Delta$ IS26 and intact  
599 *IS15DI* mobilises the *mcr-3.1* via homologous recombination through the formation of  
600 circular intermediates. The IS-mediated transposition enables the mobilisation of the *mcr-3*  
601 resistance gene between the chromosome and plasmids, which further contributes to the  
602 dissemination of resistance genes<sup>34, 35</sup>. Similar conclusion was reached with the 3535 bp  
603 circular intermediates in a study performed by Xiang *et al.* (2018),<sup>97</sup> which showed that  
604 mobilisation of the *mcr-3* core segment (*mcr-3-dgkA*) through *ISKpn40* elements facilitated  
605 its spread into various plasmids.

606 The *mcr-3.12* variant has a 99% nucleotide sequence identity with an *Aeromonas veronii*  
607 sequence<sup>91</sup> and significant (77%) amino acid sequence identity to three P<sub>ETN</sub> transferases  
608 found within the genera<sup>90, 91, 98</sup>. It is suggested that *mcr-3* genes originated from the  
609 *Aeromonas* genus, or the *mcr-3* gene is widely disseminated as an acquired resistance trait  
610 and thus also found in *Aeromonads*<sup>91</sup>. It is however thought that *mcr-3* was initially  
611 transposed from the *Aeromonas* genera to the *Enterobacteriaceae* family through ISK<sub>pn40</sub>-  
612 mediated transposition. The ISK<sub>pn40</sub> elements encode two ORF and the second ORF has a  
613 99% identity to both a transposase from *Aeromonas sp.* and an integrase from *Aeromonas*  
614 *caviae*<sup>99</sup>. This IS element is found flanking the *mcr-3* segment and was also shown to  
615 mobilise through homologous recombination<sup>52, 97</sup>. The last evidence of *mcr-3* originating  
616 from *Aeromonas* includes the presence of TnAs2 located upstream of the *mcr-3* gene<sup>90</sup>. The  
617 transposon has only been identified in *A. salmonicida* and because its sequence in pWJ1  
618 (original *mcr-3* plasmid) is a partial sequence, it is unlikely to have mobilised the *mcr-3* gene  
619<sup>90, 95</sup>. This evidence supports the possibility of the *Aeromonas* genus being a possible  
620 progenitor of *mcr-3* genes<sup>90</sup>.

621 *Mcr-3* and its variants are disseminated within *Enterobacteriaceae*, having been identified in  
622 *E. coli*, *Salmonella sp.* and *K. pneumoniae* in healthcare centres, aquaculture, wastewater, and  
623 in animals<sup>18, 34, 90, 92, 95, 98, 100</sup>. The resistance genes have been identified in both transmissible  
624 and non-transmissible plasmids such as IncA/C<sub>2</sub>, IncHI<sub>2</sub>, IncHI<sub>2A</sub>, IncF<sub>II</sub>/F<sub>IB</sub>, IncY, IncR,  
625 IncF, and IncP and in many variant mutations. The first identified *mcr-3* gene was identified  
626 on an IncHI<sub>2</sub> plasmid replicon (pWJ1) in *E. coli* isolated from pigs in China<sup>90</sup>. Thereafter,  
627 multiple *mcr-3* variants have been identified with one or more amino acid substitutions. Yang  
628 *et al.* (2020) evaluated the impact of *mcr-3* expression on bacterial fitness using two *mcr-3*  
629 variants, *mcr-3.1* and *mcr-3.5* (T488I, M23V, A456E)<sup>94</sup>. The study showed that although the  
630 expression of both variants imposed a fitness cost and impaired the cell wall integrity, the  
631 expression of *mcr-3.5* was less costly<sup>94</sup>. Yang *et al.* (2020)<sup>94</sup> showed that the amino acid  
632 substitutions A457V and T448I, seen in *mcr-3.5*, had strong compensatory effects when  
633 introduced in *mcr-3.1*. The introduction of these substitutions, individually, resulted in an  
634 increased fitness of up to 45%. However, double substitutions demonstrated a negative  
635 epistasis.

636 This study highlights an interesting concept about all *mcr* genes i.e., the *mcr* variants may  
637 encode compensatory mutations that mitigate the expression of *mcr* genes and thus, is an  
638 evolutionary mechanism for the worldwide dissemination of *mcr* genes<sup>94</sup>. Though variants

639 such as *mcr-3.10* has seven substitutions (V122G, R297L, E337K, H341Y, D358E, Q468K  
640 and I313V)<sup>92</sup> in both the putative transmembrane region and catalytic domains, these  
641 substitutions do not affect MCR-3.10's ability to confer colistin resistance. Wang *et al.*  
642 (2018d) showed that similar to the original *mcr-3*, the expression of *mcr-3.10*, results in an 8-  
643 fold increase in colistin MICs. Similar results were seen with *mcr-3.5*<sup>95</sup>.

#### 644 *Mcr-4* variant

645 *Mcr-4* was first identified in *S. Typhimurium* isolated from the caecal content of a pig at  
646 slaughter in Italy in 2013<sup>101</sup>. The *S. Typhimurium* was colistin-resistant and negative for  
647 known *mcr* genes. MCR-4 respectively has an amino acid sequence identity of 34%, 35% and  
648 49% to MCR-1, MCR-2, and MCR-3, and like other P<sub>ET</sub>N transferases, can mediate colistin  
649 resistance through Lipid A modification<sup>101</sup>. MCR-4, however, has an 82%-99% amino acid  
650 sequence identity to one large P<sub>ET</sub>N transferase found in *Shewanella* sp., and the *mcr-4.3*  
651 variant has a 100% nucleotide sequence identity to a chromosomal P<sub>ET</sub>N transferase encoded  
652 by *S. frigidimarina*<sup>98, 101, 102</sup>. *Mcr-3* and *mcr-4* are suggested to have originated from aquatic  
653 environments, as *Aeromonas* and *Shewanella* sp. are aquaculture fish pathogens that are  
654 intrinsically resistant to colistin<sup>98</sup>. The dissemination of these *mcr* genes to the  
655 *Enterobacteriaceae* family may have been carried through plasmids from the host genome.  
656 The mechanism underlining this mobilisation is yet to be discovered<sup>98</sup>.

657 *Mcr-4* was initially identified on an 8749 bp ColE10 plasmid, which encoded a RepB  
658 replicase, mobA/L mobilisation proteins, a RelE toxin and *exclI* gene<sup>101, 103</sup>. In other cases,  
659 the ColE plasmid was found to encode a RepA replicase instead of RepB. However, both  
660 plasmids showed a 99% nucleotide sequence identity to plasmids from *Pantoea* species, with  
661 a 65% coverage<sup>101-103</sup>. The *mcr-4* gene was flanked by IS5 elements on some plasmids and  
662 on other plasmids, it was flanked by an  $\Delta$ IS10 element upstream and an IS1294 element  
663 downstream<sup>103</sup>. Genetic analysis found that the ColE plasmid encodes a conserved 59-bp  
664 region upstream the *mcr-4* gene, and this region is predicted to encode the -35 (TTATTT) and  
665 -10 (AGCTAGTAT) promoter regions.<sup>102</sup> This allows for ColE plasmids to replicate  
666 independently in different bacterial species and genera<sup>101</sup>. ColE plasmids are broad-range  
667 non-conjugative plasmids whose mobilisation, however, require a helper plasmid;  
668 nevertheless, the mobilisation of the *mcr-4* gene is hypothesized to be achieved through a  
669 transposition event mediated by the IS5 element<sup>101</sup>.

670 A genomic analysis of the initial *mcr-4*-producing *S. Typhimurium* genome found the  
671 ColE10 replicon located within the host chromosome integrated within the Type 1  
672 methylation gene. Carattoll *et al.* (2017) suggest a transposition event mediated the  
673 chromosomal integration of the ColE10 plasmid<sup>101</sup>. *Mcr-4* has been isolated from both  
674 humans and animals in Spain, Belgium, Italy, and China in *Enterobacteriaceae*<sup>101, 104-106</sup>. An  
675 inactive *mcr-4.3* variant identified by Teo *et al.*<sup>105</sup> (2018) was found to encode two missense  
676 mutations, V179G and V236F, that inactivated the PEtN transferase activity<sup>102, 105</sup>. A  
677 comparative alignment of the MCR-4.3 to *MCR-1* and *MCR-2* found that the active residues  
678 were conserved in MCR-4.3<sup>105</sup>. However, an MS spectrum of lipid A in *mcr-4.3*-expressing  
679 isolates showed *mcr-4.3* failed to modify lipid A<sup>102</sup>. The transformation of *E. coli* with an  
680 *mcr-4.3* expressing vector resulted in no difference in colistin MIC values, suggesting that  
681 *mcr-4.3* does not confer colistin resistance<sup>102, 105</sup>. Thus, some compensatory mutations in *mcr*  
682 may aid in fitness cost while others such as those seen in *mcr-4.3* significantly altered the  
683 PEtN transferase activity of *mcr-4.3*<sup>102</sup>.

#### 684 *Mcr-5* variant

685 *Mcr-5* was first identified in a d-tartrate-fermenting *S. Paratyphi* B isolated from food-  
686 producing animals across Germany between 2011 and 2013. Following this discovery of *mcr-*  
687 *5*, further screening resulted in the identification of fourteen additional *mcr-5*-producing  
688 isolates. These were isolated between 2011 to 2016 in the same study<sup>107</sup>. *Mcr-5* encodes a  
689 547 amino acid PEtN transferase, which has a protein identity of 33% to 35% to other known  
690 MCR proteins i.e., MCR-1 to MCR-4. Although MCR-5 has a low identity to other MCR  
691 proteins, all five MCR proteins, i.e., MCR1, MCR-2, MCR-3, MCR-4, and MCR-5, each  
692 encode the five conserved residue viz., E248, T286, H389, D458, and H359, that are located  
693 within the catalytic centre of the periplasmic domain<sup>107</sup>. These conserved residues have been  
694 found to be essential for substrate binding and MCR activity<sup>79</sup>. The capability of *mcr-5* to  
695 confer colistin resistance was shown using the original *mcr-5*-harbouring plasmid and a  
696 plasmid vector encoding the *mcr-5* operon in a transformation experiment using both an *E.*  
697 *coli* and a wild-type *S. Paratyphi* strains. In both experiments, the transformants achieved a  
698 colistin MIC value of 8 mg/L<sup>107</sup>.

699 The MCR-5 protein has a 100% amino acid sequence identity to a PEtN transferase identified  
700 in *Pigmentiphaga* genus and *Cupriavidus gilardii*. The first 404 amino acids of the MCR-5  
701 protein also have a high identity to a hypothetical protein from *Pseudomonas aeruginosa*<sup>107</sup>.  
702 Genetic analysis of *mcr-5* found that the resistance gene is located within an operon encoding

703 a Chromate B (ChrB) protein domain responsible for regulating the expression of ChrA for  
704 chromate resistance and two ORF that encode a major facilitator superfamily (MFS) type  
705 transporter<sup>107, 108</sup>. The complete operon is located within a 7337bp Tn-3 type transposon  
706 named Tn6452<sup>52, 107</sup>, that is flanked by inverted repeats (IRs). A genetic analysis of the  
707 transposon identified *tnpA* encoding a Tn3 transposon, *tnpR* encoding a Tn3 resolvase and a  
708 *bla* gene encoding a  $\beta$ -lactamase<sup>109</sup>. Tn6452 encodes mechanisms for transposition of the  
709 *mcr-5* cassette, TnpA, and TnpR<sup>109</sup>, which allows the *mcr-5* cassette to be transferred  
710 between plasmids and chromosomes<sup>110</sup>.

711 *Mcr-5* has also been identified on Tn3-like structures that encode the ChrB gene but lacked  
712 the transposase gene and encoded an imperfect Tn3-like inverted repeats left (IRL)<sup>110-112</sup>.  
713 This structure resembles features of a miniature inverted repeat transposable element, which  
714 possess a left or right IRs but lacks a transposase gene<sup>111</sup>. Kieffer *et al.* (2019a)<sup>111</sup> suggests  
715 the acquisition of the *mcr-5* cassette was through a transposition event and although the Tn3-  
716 like structure lacks a transposase gene, it can still mobilise the cassette through a  
717 nonautonomous transposition mechanism. The *mcr-5* cassette has been identified on the host  
718 chromosome<sup>107</sup>, a multicopy ColE-type plasmid<sup>107, 110, 112, 113</sup> and on an IncX plasmid<sup>110</sup>.  
719 The presence of *mcr-5* cassette on a multicopy plasmid (ColE-type) thus means multiple  
720 copies of *mcr-5* transposon will exist within the cell. Borowiak *et al.* (2017)<sup>107</sup> found that  
721 there is a higher degree of colistin resistance (8 mg/L) in isolates harbouring ColE-type  
722 plasmids encoding *mcr-5* than in isolates with a single copy of the *mcr-5* integrated within  
723 the chromosome (4 mg/L). The ColE type plasmids are, however, non-conjugative and thus  
724 the presence of the *mcr-5* cassette on an IncX plasmid allows for horizontal transfer and  
725 dissemination of resistance gene between different bacterial genera and species<sup>109, 111</sup>.

#### 726 *Mcr-7 variant*

727 *Mcr-7.1* was first identified in chicken in China<sup>114</sup>. It has thereafter been identified in  
728 environmental samples<sup>115, 116</sup> and faecal samples in Brazil<sup>117</sup>. The putative PETN transferase  
729 has a 78% nucleotide sequence identity to part of the *mcr-3* gene<sup>114</sup>. Genetic analysis of *mcr*-  
730 *7.1* identified a 381 bp ORF encoding the diacylglycerol kinase, *dgkA*, downstream of *mcr*-  
731 *7.1*. The *dgkA* has an 82% nucleotide sequence identity to *Aeromonas*<sup>114</sup>. Yang *et al.* (2018)  
732<sup>114</sup> suggests, like *mcr-3*, *mcr-7.1* originates from *Aeromonas*. This was derived based on the  
733 close genetic distance between MCR-3 and MCR-7.1 found during a phylogenetic analysis  
734 and the presence of *dgkA* gene downstream both *mcr-3* and *mcr-7.1*. The ORF sequence  
735 found upstream the *mcr-7.1* gene has an 81% nucleotide sequence identity to a putative

736 phosphodiesterase gene found in *Aeromonas*<sup>114</sup>. This evidence suggests that the *Aeromonas*  
737 genus is a possible progenitor of *mcr-7.1*.

738 The *mcr-7.1* encodes a 539 amino acid PEtN transferase that confers colistin resistance  
739 during conjugative experiments<sup>114</sup>. The protein is made up of two domains, which resembles  
740 a similar structure of MCR-3. *Mcr-7.1* was identified on a self-transmissible IncI<sub>2</sub> type  
741 plasmid with no ISs in its environment; hence, the dissemination of *mcr-7.1* may be achieved  
742 through plasmid mobilisation<sup>114</sup>.

#### 743 *Mcr-8 variant*

744 *Mcr-8* was initially identified in *K. pneumoniae* from a swine faecal sample in China<sup>118</sup>.  
745 Conjugation assays found that it is a functional PEtN transferase and its expression resulted  
746 in a four- and eight-fold increase in colistin MIC.<sup>118-120</sup> MCR-8 mediated PEtN modification,  
747 which was identified using a MALDI-TOF-based technique that discriminates between  
748 colistin resistance mechanisms, i.e *mcr*-expression or chromosomal-mutations<sup>120</sup>. BLASTn  
749 analysis showed that *mcr-8* has a 50.23% nucleotide and 39.96% amino acid sequence  
750 identity to part of *mcr-3* but has 30% to 40% amino acid sequence identity to other MCR  
751 proteins. Characterisation of MCR-8 using RaptorX predicted that MCR-8, like other MCR  
752 proteins, is made up of two domains: domain one consisting of a five transmembrane  $\alpha$ -helix,  
753 and domain 2 consisting of the putative catalytic centre<sup>118</sup>. Wang *et al.* (2018c)<sup>118</sup> performed  
754 sequence alignment of all eight MCR proteins and found that the active site residues (E246,  
755 T285, K333, H395, D465, H466, E468, H478) necessary for enzyme activity of MCR  
756 proteins and the six-cysteine residues required for the three disulphide bonds found in the  
757 catalytic domain were highly conserved across all 8 MCR proteins<sup>118, 119</sup>.

758 Analysis of *mcr-8*'s genetic environment found that it is usually flanked by two complete  
759 IS903 elements, with both 50 bp IRL and IRR located upstream, and downstream,  
760 respectively<sup>119, 121</sup>. It is also associated with *ISEcl1* and *ISKpn26*, located upstream and  
761 downstream, respectively<sup>122</sup>. Yang *et al.* (2019b)<sup>122</sup> found that the insertion of *ISEcl7* was  
762 an independent event and may not be involved in mobilising *mcr-8*. The formation of circular  
763 intermediates via *IS903B* elements to mobilise *mcr-8* remains unknown; however, the  
764 association of *mcr-8* to ISs facilitates both the transmission of *mcr-8* and its close association  
765 with other resistance genes<sup>121</sup>; specifically, it has been found associated with aminoglycoside  
766 resistance genes<sup>121</sup>,  $\beta$ -lactamase genes<sup>119</sup> and *tmexCDI-toprJ1* genes that encode a novel  
767 plasmid-mediated efflux pump that confers resistance to tigecycline<sup>123</sup>.



768 *Mcr-8* is commonly found in *K. pneumoniae*<sup>118, 120, 121, 123-126</sup>, Wang *et al.* (2018c)<sup>118</sup>  
769 performed a phylogenetic analysis of the *mcr*-positive *K. pneumoniae* isolates identified in  
770 their study and found that the *mcr*-positive *K. pneumoniae* were genetically diverse.  
771 *K. pneumoniae* express colistin resistance usually through chromosomal mutations<sup>10</sup>. Wu *et*  
772 *al.* (2020)<sup>121</sup> suggest the expression of *mcr-8* may have synergistic effects with the  
773 chromosomal mutations within the two-component system (TCSs), resulting in heterogenous  
774 colistin resistance mechanisms<sup>121</sup>. *Mcr-8* has also been identified in *Klebsiella*  
775 *quasipneumoniae*<sup>122</sup> and *R. ornithinolytica* as well as on a diverse range of Inc groups:  
776 IncFII, IncFIA, IncFIB, IncQ, IncR, IncFIIK, IncFIA and IncA/C; these will expectedly  
777 accelerate the dissemination of *mcr-8* and other ARGs within and outside *Enterobacteriaceae*  
778<sup>119, 121</sup>.

#### 779 *Mcr-9* variant

780 *Mcr-9* gene was identified by Carroll *et al.* (2019)<sup>127</sup> in a colistin susceptible *S.*  
781 *Typhimurium* isolated from a human patient in Washington State in 2010. A BLAST analysis  
782 identified the gene in 355 genomes, where 65 were encoded on a plasmid replicon of the  
783 same contig<sup>127</sup>. The presence of *mcr-9* on a plasmid replicon facilitates its dissemination  
784 globally and across *Enterobacteriaceae*<sup>127</sup>. It has thereafter been identified in more clinical  
785 settings<sup>128-135</sup> and in food-producing animals<sup>136, 137</sup>. Among the 355 genomes, 65 were  
786 associated with a plasmid replicon, which may facilitate their dissemination globally<sup>127</sup>. *Mcr-*  
787 *9* cassette is usually located either on a IncHI<sub>2</sub> and/or IncHI<sub>2A</sub> replicon or chromosomally  
788 encoded<sup>127, 133, 138, 139</sup>. It is widely distributed within *Enterobacteriaceae*, particularly within  
789 *Enterobacter* sp.<sup>129, 130, 132, 133, 135</sup>, *Citrobacter telavivum*<sup>134</sup>, *Salmonella* sp.<sup>127, 137, 138</sup> and *E.*  
790 *coli*<sup>136, 140</sup>.

791 *Mcr-9* is always associated with *wbuC*, encoding a cupin fold metalloprotein, located  
792 downstream the gene<sup>131, 135, 140</sup>. The amino acid sequence of *mcr-9* closely resembles that of  
793 *mcr-3* and *mcr-7*, at a 99.5% coverage; it has amino acid sequence identity of 64.5% to *mcr-*  
794 *3.17* and 63% to *mcr-7*<sup>127, 140</sup>. A three-dimensional structural model analysis of all nine *mcr*  
795 homologues based on the amino acid sequences of each showed that *mcr-9* was closely  
796 related to *mcr-3*, *mcr-4* and *mcr-7* at a structural level<sup>127</sup>. Further, all nine *mcr*-homologues  
797 had a high level of conservation for both domains (transmembrane domain and catalytic  
798 domain): the structural models showed the amino acids and structural elements were  
799 conserved in the C-terminal catalytic domain and the structural elements in the membrane-  
800 anchored N-terminal domain<sup>127</sup>. A database search using *mcr-9* as a template identified a

801 chromosomal-encoded *mcr-9*-like gene within a *Buttiauxella* species isolate, a member of the  
802 *Enterobacteriaceae*<sup>140</sup>. The identified *mcr*-like protein, MCR-BG, was isolated from *B.*  
803 *gaviniae*, and was found to have an 84% amino acid identity to the MCR-9 enzyme; MCR-  
804 BG, similar to *mcr-9*, has the *wbuC* gene located downstream<sup>140</sup>.

805 Similar results were reported by Yuan *et al.* (2019) with a PEtN transferase isolated from *B.*  
806 *brennerae*. It had 86.83% protein sequence identity to *mcr-9* at a 100% coverage<sup>135</sup>. Further,  
807 the *wbuC* located adjacent the *mcr-9* gene was found to be homologous to that of *Buttiauxella*  
808 with a 86% amino acid identity at a 98% coverage<sup>135</sup>. This evidence suggests that *mcr-9* may  
809 have originated from *Buttiauxella* species and disseminated to the rest of the  
810 *Enterobacteriaceae* family.

811 The dissemination of *mcr-9* may have been aided by its association with IS elements flanking  
812 the cassette<sup>133</sup>. The *mcr-9* cassette has been found flanked with IS903 and IS903-like  
813 elements upstream as well as ISIR, IS26-like, and IS15DII located downstream in multiple  
814 reports<sup>132, 133, 135, 140</sup>. The first report of the *mcr-9* cassette encoded the *wbuC* gene, a TCS  
815 encoding *qseC* and *qseB* genes,  $\Delta$ ISIR and a remnant of  $\Delta$ silR, encoding a transcriptional  
816 regulatory protein, all of which are located downstream of the *mcr-9* gene. The *mcr-9* cassette  
817 is thereafter flanked by intact IS903 elements<sup>135</sup>. Though two copies of an intact IS element  
818 should be able to form a composite transposon or a circular intermediate, an inverse-PCR  
819 assay failed to detect any intermediates<sup>135</sup>. However, the identification of IS903-like  
820 elements associated with *mcr-9* genes suggests the acquisition of the cassette through an  
821 IS903 dependent mechanism. In some reports, the 3' region of *mcr-9* is adjacent to *copS*  
822 (three copper resistance membrane-spanning proteins that includes *rcnA*, *rcnR* and a domain-  
823 containing DUF4942)<sup>132, 139</sup>.

824 The *mcr-9* protein as stated above has high levels of conservation within both PEtN  
825 transferase domains<sup>127</sup>. Notwithstanding, multiple reports have shown *mcr-9*-harbouring  
826 isolates that are susceptible to colistin<sup>127, 129, 130</sup>, with the colistin MIC value usually less than  
827 2 mg/L<sup>128</sup>. Kieffer *et al.* (2019b)<sup>140</sup> and Carroll *et al.* (2019)<sup>127</sup> performed induction  
828 experiments that conferred clinical resistance. However, the mechanism underlining each  
829 experiment remains unknown. Carroll *et al.* (2019) identified a conserved  $\sigma^{70}$  family-  
830 dependent -35 and -10 regions and an inverted repeat in the promoter of *mcr-9* genes in the  
831 database. The authors suggest that the conserved DNA motif in the *mcr-9* promoter is likely a  
832 recognition sequence for a transcription regulator, which might be needed for full expression

833 of the *mcr-9* gene<sup>127</sup>. Kieffer *et al.* (2019b)<sup>140</sup> suggested the QseC-QseB TCS played a role  
834 in inducing *mcr-9* expression to confer colistin resistance in the presence of sub-inhibitory  
835 concentration of colistin; however, multiple reports have failed to replicate these results<sup>130</sup>,  
836<sup>134, 138, 139</sup>. In these studies, the *mcr-9*-harbouring isolates encoding the QseC-QseB TCS  
837 regulatory genes were fully susceptible to colistin<sup>134, 138</sup>. Tyson *et al.* (2020)<sup>138</sup> suggests the  
838 induction and overexpression of *mcr-9* may be context-dependent and be different in different  
839 strain backgrounds. The expression of *mcr-9* in a pBAD vector conferred colistin resistance  
840<sup>141</sup> and Kieffer *et al.* (2019b)<sup>140</sup> has shown that MCR-9 can mediate Lipid A modifications.  
841 However, the genes and molecules required to regulate *mcr-9* expression in its own genomic  
842 environment remains unknown<sup>130</sup>.

#### 843 *Mcr-10* variant

844 The *mcr-10* gene was first identified in an *Enterobacter roggenkampii* clinical strain in China  
845<sup>141</sup>. It has a nucleotide sequence identity and amino acid sequence identity of 79.69% and  
846 82.93% respectively to *mcr-9*<sup>141</sup>. Therefore, like *mcr-9*, the *mcr-10* gene shares a significant  
847 amino acid identity to the chromosomally encoded *mcr*-like PEtN transferase of *Buttiauxella*  
848 species<sup>141</sup>. *mcr-10* encodes a putative PEtN transferase that is made up of an N-terminal  
849 membrane-anchored domain and a C-terminal soluble catalytic domain, which have high  
850 levels of conservation to both MCR proteins and the MCR-B of various *Buttiauxella* species  
851<sup>141, 142</sup>. Xu *et al.* (2021) evaluated whether *mcr-10* can mediate colistin resistance and  
852 compared its activity to that of *mcr-1* and *mcr-9*. The study showed that the activity of *mcr-*  
853 *10* against colistin is lower than that of *mcr-9* but is able to mediate colistin resistance with an  
854 MIC value of 2.5 mg/L<sup>142</sup>. This shows that *mcr-10* is functional and thus aids the host to  
855 survive colistin selective pressure<sup>142</sup>. Xu *et al.* (2021) again showed that the expression of  
856 *mcr-10* is inducible under colistin resistance and further found an upregulation of *phoP-phoQ*  
857 TCS genes, producing a colistin MIC value of 8 mg/L. The authors suggested that *mcr-10*  
858 might co-function with PhoPQ to mediate high levels of colistin resistance<sup>142</sup>.

859 *Mcr-10* has been identified on IncFIA and IncFIB plasmids<sup>141-144</sup> and adjacent to a *XerC*  
860 gene, which encodes a XerC type tyrosine recombinase found to mobilise adjacent genetic  
861 components such as antimicrobial resistance genes<sup>141</sup>. Thus, *mcr-10* would be presumed to  
862 have disseminated across *Enterobacteriaceae* family but has only been identified commonly  
863 in *Enterobacter roggenkampii*<sup>141, 142, 145</sup> and once in *Cronobacter sakazakii*<sup>143</sup>. Wang *et al.*  
864 (2020a) and Xu *et al.* (2021) suggest that *E. roggenkampii* is an important reservoir of *mcr-*  
865 *10*.

866 In the initial identification of *mcr-10*, the gene was adjacent XerC and flanked by two intact  
867 IS903 elements which could form a composite transposon with the potential to mediate  
868 mobilisation of the *mcr-10* gene<sup>141</sup>. The analysis of the immediate genetic environment of  
869 the IS903 element found the absence of direct repeats that are generated during an insertion  
870 event; thus, the acquisition of the region bracketed by the IS903 elements was not due to an  
871 insertion event<sup>141</sup>. The presence of an a  $\Delta$ ISEc36 downstream the *mcr-10* gene was reported  
872 to make it impossible to identify the recombination sites that the XerC-type tyrosine  
873 recombinase recognizes<sup>141</sup>. Thus, the acquisition events of *mcr-10* into pMCR-10\_09006  
874 remains unknown<sup>141</sup>. *Mcr-10* has thereafter been<sup>145</sup> identified with various insertion  
875 sequences, including complete and truncated remnants of IS26 and ISKpn26, complete  
876 sequences of ISEc36 and IS1, a  $\Delta$ ISEc11-like elements and recently, a new IS element  
877 designated ISCrSal<sup>143, 145</sup>. The identification of various IS elements downstream *mcr-10*-  
878 *xerC* suggests that this region might be a hotspot for insertions of MGEs<sup>141, 142</sup>. The  
879 acquisition of *mcr-10* is presumed to be through site-specific recombination;<sup>143</sup> however,  
880 evidence of mobilisation of *mcr-10* is scarce.

#### 881 *Risk factors for acquiring mcr genes*

882 Antimicrobials are commonly administered by farmers to pigs and poultry for prophylaxis,  
883 therapeutics, and growth promotion in livestock<sup>146-148</sup>. Studies around the world have shown  
884 that the use of colistin as a growth promoter results in a high frequency of *mcr-1* positive,  
885 colistin resistant *Enterobacteriaceae* (MPCRE) because of the high selective pressure in the  
886 veterinary environment. The selection pressure led to the acquisition and spread of *mcr-1*  
887 genes<sup>11, 146, 148-152</sup>. The presence of *mcr-1* in food animals had a serious potential to spread  
888 MPCRE to humans via foodborne transmission<sup>11, 150, 151</sup>.

889 The pharmaceutical form of colistin is indicated for oral administration and is present in a  
890 powder or solution form<sup>152</sup>. Studies have shown that the drug is poorly absorbed in the  
891 digestive tract after oral administration and can be excreted in high levels through the faeces  
892<sup>1, 150, 152</sup>. This results in the presence of colistin or its active metabolites in the environment  
893 alongside the MPCRE isolates from the animal faeces<sup>150</sup>. Xia *et al.* (2019)<sup>153</sup> measured the  
894 concentration of colistin in animal feeds and fresh manure in five swine farms and found that  
895 the average concentration of colistin in animal feed on farm 4 was 60 mg/kg, which was  
896 scientifically higher than other farms. The fresh manure samples collected on farm 4 had the  
897 highest concentration of 17,383  $\mu$ g/kg. Other farms had colistin concentrations in their fresh

898 manures ranging from 140 µg/kg in farms 1, 2 and 5, to 7,529 µg/kg in farm 3<sup>153</sup>. The  
899 researchers also discovered a strong relationship between colistin concentration and the  
900 relative abundance of *mcr-1* genes in fresh manure<sup>153</sup>. The use of this manure as a fertilizer  
901 in agriculture or feeding farmed fish can result in the contamination of agriculture and, in  
902 some cases, the aquatic environment, polluting rivers and lakes<sup>150, 154</sup>.

903 Luo *et al.* (2017) cultured an *mcr-1* producing *Raoultella ornithinolytica*, a member of the  
904 *Enterobacteriaceae* family commonly found in soil, aquatic, and botanical environments, in  
905 retail vegetables in China. They emphasized that using animal excrements contaminated with  
906 colistin and/or MPCRE can cause contamination and spread of MPCRE to fresh vegetables.  
907<sup>154</sup>. There is, however, no epidemiological data on the contamination of rivers and lakes by  
908 MPCRE-contaminated animal excrements and thus, no evidence of the spread of MPCRE to  
909 the aquaculture<sup>150</sup>. However, the presence of *mcr-1*-producing *E. coli* has been reported in  
910 duck and fish samples in China. Shen *et al.* (2019)<sup>155</sup> found a potential spread of *mcr-1*  
911 producing *E. coli* (MPEC) from aquaculture supply chain to humans through aquatic food<sup>150</sup>,  
912<sup>155</sup>. Other examples of the spread of MPCRE into the environment includes the identification  
913 and isolation of MPCRE in blowflies (*Chrysomya* sp.)<sup>156</sup> and black kites<sup>54</sup>. Both cases are of  
914 public concern because of the potential transmission into human communities.

915 Yang *et al.* (2019a)<sup>156</sup> showed that blowflies may serve as an environmental reservoir and  
916 vector of MPCRE between animals, humans, the environment, and waste (landfills and  
917 sewage water)<sup>156</sup>. The presence of MPCRE in Black kites in Russia highlights the spread of  
918 *mcr-1* genes into both wildlife and the environment. Tarabai *et al.* (2019)<sup>54</sup> hypothesized that  
919 the acquisition of MPCRE was either through contact with the Biysk Municipal landfill or  
920 through their food, which was commonly found along the Biya River near their nest. Black  
921 kites can thereafter spread MPCRE along their long migratory pathways<sup>54</sup>. The *mcr-1* gene is  
922 commonly found on transferable plasmids, and thus the presence of *mcr-1* producing isolates  
923 in the microbiota of insects and wildlife increases the possibility of horizontal transfer of  
924 *mcr-1* genes alongside other resistance genes within the microbiota. This increases the  
925 environmental gene pool and the spread of multi-drug resistant (MDR) pathogens within  
926 insects and wildlife<sup>156</sup>.

927 There are therefore multiple reservoirs highlighted above with the potential of spreading  
928 towards humans because of the close association between humans and the environment. A  
929 study in Vietnam showed that the farmers that are in contact with animals under colistin  
930 selection pressure have a high risk of being colonized by MPCRE<sup>151</sup>. Trung *et al.* (2017)<sup>151</sup>

931 found that chickens associated with colistin administration had a high carriage of *mcr-1*  
932 producing isolates and the colonization of humans was through exposure to the chickens. The  
933 chicken faecal samples had a high prevalence of *mcr-1* (59.4%) and zoonotic transmission  
934 prevalence was 34.7% in farmers. Another possible route of transmission of MPCRE from  
935 animals under colistin pressure was foodborne transmission<sup>11, 157, 158</sup>. Monte *et al.* (2017a)  
936 found that chicken meat was acting as a reservoir of MPEC. A study performed by Shen *et al.*  
937 (2018)<sup>150</sup> found a positive correlation between MPEC carriage in the human normal flora and  
938 the consumption of farm animals, which included pork and sheep. The correlation analysis  
939 also proposed a possible transmission of MPEC from aquatic food to humans<sup>150</sup>. This data is  
940 a single example that highlights the presence of MPCRE in food-producing animals and the  
941 transmission route of MPCRE from colistin-exposed animals to humans, which impacts  
942 public health care.

943 This therefore led to the ban on colistin use for growth promotion and disease prevention in  
944 the food industry to preserve their effectiveness in human medicine as their use contributes to  
945 the rising threat of antibiotic resistance<sup>159</sup>. Randall *et al.* (2018)<sup>160</sup> also demonstrated that  
946 discontinuing colistin in farming can result in the elimination of *mcr-1*. This longitudinal  
947 study evaluated the presence of *mcr-1* in pig faeces and slurry at two time points<sup>160</sup>. At the  
948 beginning of the study, the majority of the pigs were colonized by MPEC. Twenty months  
949 after cessation of colistin use and implementation of hygiene and other measures, MPEC was  
950 not detected in samples. These results thus highlight that the use of colistin is the driving  
951 force behind the spread of colistin resistance genes and its stability in the population<sup>160</sup>. The  
952 integration of *mcr-1*, however, into conjugative plasmids encoding other resistance genes  
953 allows for the use of other antibiotics such as quinolones and extended spectrum  
954 cephalosporins to simultaneously co-select for *mcr-1*, allowing for its stability and  
955 dissemination<sup>146, 161, 162</sup>. This, thus, creates severe challenges for controlling the selection and  
956 subsequent transmission of *mcr-1* genes<sup>163</sup>.

957 After the first detection of *mcr-1* by Liu *et al.* (2016), *mcr-1* genes have been detected in  
958 animals, the environment, and humans. Initially, the detection of *mcr-1* genes in humans was  
959 associated with the risk factors mentioned above: contact with farm animals, ingestion of  
960 contaminated farm food, or fresh vegetables. Epidemiology studies that identified *mcr-1*  
961 genes in the clinical settings were accompanied with a questionnaire to identify the  
962 epidemiological exposure. In countries such as Finland, where the use of colistin is restricted  
963 for rare clinical indications, the first detection of the *mcr-1* gene was identified in a healthy

964 male with previous history of travelling abroad, 6 months before faecal sampling <sup>164</sup>.  
965 Traveling to other countries has been shown to increase the risk of acquiring *mcr-1* positive  
966 isolates, particularly in patients who consumed meat while traveling abroad <sup>164, 165</sup>. The use of  
967 antibiotics prior to hospitalization or infection has been seen as an important risk factor for a  
968 multidrug resistant organism (MDRO) infection <sup>165</sup>. An epidemiological and clinical study  
969 performed by Wang *et al.* (2017) <sup>166</sup> discovered that MPEC can acquire other resistance  
970 genes, and thus previous use of antibiotics such as carbapenems and fluoroquinolones was  
971 associated with an increased risk of infection by MPEC <sup>166</sup>. Thus, the administration of  
972 antibiotics in clinics simultaneously promotes the co-selection and the preservation of colistin  
973 resistance genes <sup>167</sup>.

974 An interesting possible transmission of MPEC is between companion animals and humans. A  
975 worker at a pet shop with no prior antibiotic use or travelling abroad was identified carrying  
976 an MPEC <sup>168</sup>. A faecal screening of the pets residing where the man worked identified 4 dogs  
977 and 1 cat with an *mcr-1* positive isolate. Zhang *et al.* (2016) <sup>168</sup> suggested companion animals  
978 as a possible reservoir of colistin-resistant *E. coli*, facilitating the spread of colistin resistance  
979 genes within the community.

980 *Current and future perspectives on treating mcr-mediated colistin resistance*

981 *Clustered regularly interspaced short palindromic repeats (CRISPR)*

982 Clustered regularly interspaced short palindromic repeats (CRISPR) has been exploited and  
983 developed within molecular biology as a site-specific tool for genetic engineering <sup>169</sup>, and in  
984 regards to resistance, as a tool to deliver a programmable DNA nuclease (CRISPR-Cas9) into  
985 an MDR-pathogen to eliminate the resistance gene or plasmid <sup>170</sup>. Dong *et al.* (2019) <sup>170</sup>  
986 developed a conjugative CRISPR-Cas9 system that aimed to remove plasmids harbouring the  
987 *mcr-1* gene from bacteria. The system targeted the *mcr-1* gene and the authors found that the  
988 formation of DSBs during the elimination of the resistance gene resulted in the elimination of  
989 the whole plasmid in recipient cells <sup>170</sup>. This thereafter sensitized the recipient cells to  
990 colistin. Dong *et al.* (2019) <sup>170</sup> further found that the cells are thereafter immune against the  
991 *mcr-1* gene. Wang *et al.* (2019a) <sup>171</sup> used the same concept but developed the tool to remove  
992 both *mcr-1*-harbouring plasmids and MDR plasmids present in recipient cells using partial  
993 sequences of the targeted plasmids. He *et al.* (2021) <sup>172</sup> used the tool to eliminate both  
994 chromosomal and plasmid-borne *mcr-1* genes in *E. coli*. The CRISPR-Cas9 system was  
995 designed to target IS*Ap11*, which eliminated *mcr-1* harbouring plasmids, and in the case of  
996 chromosomally encoded *mcr-1*, cell death was seen. Similar results were achieved <sup>170</sup>, where

997 recipient cells further acquired immunity against the acquisition of the exogenous *mcr-I*  
998 containing plasmid <sup>172</sup>. These studies show that CRISPR-Cas9 system is an efficient tool for  
999 plasmid curing and to sensitise clinical isolates to antibiotics in vitro <sup>170, 171</sup>. This tool can be  
1000 optimized for therapeutic application for the elimination of antibiotic genes from resistance  
1001 reservoirs such as animal guts with prior exposure to antibiotics, the human microbial flora or  
1002 the bacteria in natural settings such as wastewater, farms or hospital settings <sup>170</sup>.

1003 The CRISPR-Cas9 system is however made up of highly anionic nucleic acids and proteins  
1004 that cannot penetrate the cell membrane into cells and thus requires a delivery vehicle. Sun *et*  
1005 *al.* (2017c) <sup>173</sup> explored Cathelicidins, which are short cationic antimicrobial peptides, as a  
1006 plasmid delivery system. The study evaluated the use of BMAP-27 to increase the efficiency  
1007 of plasmid transfer of the CRISPR-Cas9 system and found that pCas::*mcr* exhibited better,  
1008 efficient, and specific antimicrobial effects with the help of BMAP-27 <sup>173</sup>. The CRISPR-Cas9  
1009 system is a powerful tool for genome editing, its development into targeting multiple genes  
1010 with one use <sup>171</sup>, could aid in the removal of *mcr* variants in resistance reservoirs and in  
1011 clinical settings to restore colistin activity.

1012 In the meantime, there are multiple studies evaluating existing antibiotics for activity against  
1013 *mcr*-producing isolates and synergy combinations.

#### 1014 *Novel antibiotics*

1015 There are multiple novel antibiotics that have been found to have activity against *mcr-I*-  
1016 producing isolates, including eravacycline <sup>6, 174</sup> and plazomicin <sup>175</sup>. Eravacycline is a broad-  
1017 spectrum synthetic tetracycline that has been proven to be effective against clinically  
1018 important MDR pathogens, including both Gram-negative and gram-positive bacteria <sup>174</sup>.  
1019 Fyfe *et al.* (2016) <sup>6</sup> found that eravacycline had a bactericidal effect against *mcr*-producing  
1020 isolates from *Enterobacteriaceae*. The study further showed that although the overexpression  
1021 of *mcr-I* increased colistin MIC values by 64-folds, there was no effect on eravacycline  
1022 susceptibility <sup>6</sup>. Eravacycline activity was thereafter evaluated against 336 isolates collected  
1023 from hospitals across China and was found to exhibit a good efficacy against all strains <sup>174</sup>.  
1024 These isolates included Extended spectrum  $\beta$ -lactamase (ES $\beta$ L) and carbapenemase-  
1025 producing *Enterobacteriaceae*, *mcr*-producing *Enterobacteriaceae* and *A. baumannii*,  
1026 vancomycin-resistant *Enterobacteriaceae*,  $\beta$ -lactamase producing *Haemophilus influenzae*,  
1027 penicillin-resistant *Streptococcus pneumoniae* and lastly, methicillin-resistant *Staphylococcus*



1028 *aureus* (MRSA), thus showing a positive potential to treat current drug-resistant bacterial  
1029 infections<sup>174</sup>. This, however, also puts eravacycline at risk of being overused.

1030 Plazomicin is a novel broad-spectrum semi-synthetic aminoglycoside that was derived from  
1031 Sisomicin. It has been shown to have activity against a broad spectrum of MDR pathogens,  
1032 including ES $\beta$ L- and carbapenemase-producing isolates and fluroquinolone-resistant isolates  
1033<sup>175</sup>. Denervaud-Tendon *et al.* (2017)<sup>175</sup> evaluated the bactericidal activity of plazomicin  
1034 against colistin-resistant Enterobacterial strains, which harboured different colistin resistance  
1035 mechanisms i.e., chromosomal-encoded, *mcr-1*-expressing, and intrinsically resistant strains.  
1036 Plazomicin activity was further compared with other aminoglycoside antibiotics viz.,  
1037 amikacin, gentamicin, and tobramycin. Plazomicin displayed potent activity against the  
1038 clinical colistin-resistant Enterobacterial strains irrespective of their resistance mechanisms.  
1039 However, those that were intrinsically resistant (*Serratia*, *Proteus*, *Morganella* and *Hafnia*)  
1040 had a higher MIC value<sup>175</sup>.

1041 Denervaud-Tendon *et al.* (2017) also found that amongst all aminoglycoside antibiotics  
1042 tested, plazomicin was the most potent. They lastly also found that plazomicin's activity is  
1043 restricted by aminoglycoside resistance mechanisms such as the 16S rRNA methylase-  
1044 encoding gene, which resulted in an elevated plazomicin MIC value (>128 mg/L).  
1045 Plazomicin, however, like other aminoglycosides, has a rapid bactericidal activity with  
1046 favourable chemical and pharmacokinetics properties and thus could be incorporated into  
1047 therapeutic treatments against *mcr*-producing bacterial infections<sup>175</sup>.

1048 Artilysin ® Art-175 is a novel engineered enzyme-based experimental therapeutic derived  
1049 from endolysins produced by lytic bacteriophages. These endolysins degrade the bacterial  
1050 cell wall resulting in cell lysis, which occurs at the end of the bacteriophage infection cycle  
1051<sup>176</sup>. Artilysin ® Art-175 is made up of the outer membrane destabilizing peptide, which is  
1052 fused to an endolysin, it targets the anionic lipopolysaccharide molecules of the outer  
1053 membrane of Gram-negatives. Schirmeier *et al.* (2018)<sup>177</sup> evaluated the potential of Art-175  
1054 against pan-drug resistant isolates, including colistin-resistant MPEC and further determined  
1055 the potential of cross-resistance between colistin and Art-175. Art-175 was highly  
1056 bactericidal against the tested isolates, which were more susceptible to Art-175 than the  
1057 colistin-susceptible isolates<sup>177</sup>. Hence, there is no cross-resistance between the two peptides,  
1058 highlighting Art-175 as a potent solution against *mcr*-producing isolates<sup>177</sup>.

1059 *Antimicrobial peptides*

1060 Bacteriocins are ribosome-synthesized antimicrobial peptides (AMPs) produced by both  
1061 Gram-positive and Gram-negative bacteria. Studies have shown that bacteriocins produced  
1062 by lactic acid bacteria (LAB) are cationic peptides with bactericidal activity that act on the  
1063 cytoplasmic membrane of susceptible microorganisms<sup>178</sup>. The LAB bacteriocins create pores  
1064 in the membrane, resulting in intracellular damage. Al Atya *et al.* (2016)<sup>4</sup> evaluated the  
1065 combinations of nisin and enterocin DD14 LAB bacteriocins with colistin to eradicate  
1066 colistin-resistant *E. coli* strains in either planktonic states or in biofilm. Whilst colistin and  
1067 the bacteriocins were ineffective as monotherapy against both planktons and biofilms,  
1068 colistin-nisin and colistin-enterocin DD14 combination were able to reduce the number of  
1069 colony-forming units (CFU) of strains in both planktonic and biofilm states. The triple  
1070 combination of all three molecules, colistin-nisin-enterocin DD14, completely eradicated all  
1071 *E. coli* strains, including colistin-resistant phenotype<sup>4</sup>. LAB bacteriocins alone cannot  
1072 penetrate the outer membrane. However, with the disruption of the LPS via colistin activity,  
1073 the LAB bacteriocins may thereafter act upon the cytoplasmic membrane<sup>4</sup>. Al Atya *et al.*  
1074 (2016)<sup>4</sup> therefore highlights LAB bacteriocins as a potential novel adjunctive treatment for  
1075 colistin-resistant MPEC infections.

1076 There have been multiple reports of AMPs that have been developed for treating MDR  
1077 pathogens, which have a similar mode of action as colistin<sup>179</sup>. Van der Weider *et al.* (2019)  
1078 evaluated the antimicrobial activity of two novel AMPs, AA139 and SET-MM3. AA139  
1079 originates from a marine lugworm, *Arenicola marina*, AMP arenicin-3. SET-MM3 is a  
1080 synthetic tetra-branched peptide linked by a lysine core<sup>179</sup>. The antimicrobial activity of  
1081 these AMPs was evaluated against a collection of clinically and genotypically diverse *K.*  
1082 *pneumoniae* with different antimicrobial susceptibility profiles. Both AMPs, AA139 and  
1083 SET-M33, further showed a concentration-dependent bactericidal effect across all isolates,  
1084 meaning that the susceptibility profile of both AMPs was unaffected by the resistance profile  
1085 and colistin susceptibility of the isolates<sup>179</sup>. The AMPs were effective against the colistin-  
1086 resistant strains, and no cross-resistance was observed between the AMPs and colistin. Thus  
1087 the antimicrobial activity of AA139 and SET-M33 should further be investigated across other  
1088 Gram-negatives to evaluate its spectrum of bactericidal activity<sup>179</sup>.

1089 Cross-resistance between several human cationic AMPs (CAMPs) and polymyxins has been  
1090 previously reported in P<sub>ET</sub>N transferase-producing *Haemophilus ducreyi* and *Campylobacter*  
1091 *jeyuni* but rarely in *Enterobacteriaceae*. These CAMPs are part of the intrinsic human

1092 immune system and act against Gram-negative bacteria by disrupting the outer and inner  
1093 membrane through electrostatic interaction, similar to colistin's mechanism of action<sup>180</sup>.  
1094 Dobias *et al.* (2017)<sup>180</sup> selected a few widely distributed CAMPs in humans, LL-37,  $\alpha$ -  
1095 defensin 5 (HD5) and  $\beta$ -defensin 3 (HDB3) and evaluated whether cross-resistance between  
1096 CAMPs and polymyxin would be observed in MPEC. Susceptibility of *E. coli* to the different  
1097 CAMPs selected varied depending on the CAMP molecule rather than the entire CAMP  
1098 family. It further showed that the production of MCR proteins did not confer cross-resistance  
1099 with the human CAMPs selected<sup>180</sup>.

1100 However, the CAMPs activity studied by Dobias *et al.* (2017),<sup>180</sup> compared to other studies  
1101<sup>181</sup>, shows that factors such as bacterial species, level of resistance, and colistin resistance  
1102 mechanisms may affect the bactericidal levels of CAMPs<sup>180, 181</sup>. Therefore, although *mcr*  
1103 production did not affect the bactericidal activity of CAMPs against *E. coli*, it needs to be  
1104 evaluated across *Enterobacteriaceae* and other Gram-negative bacteria to see how different  
1105 colistin resistance mechanisms affect the CAMPs' bactericidal effect. Guachalla *et al.* (2018)  
1106<sup>182</sup> further evaluated the effectiveness of other derivatives of the human immune system against  
1107 a clinical MPEC strain. This includes humanized monoclonal antibodies that have been  
1108 previously shown to target the LPS O25b antigen that is associated with *E. coli* ST131-H30  
1109<sup>182</sup>. The expression of *mcr-1* does not affect the binding of ASn-4 to the LPS's O-antigen and  
1110 the integration of the complement membrane-attack complex (MAC) into the LPS-modified  
1111 outer membrane<sup>182</sup>. This means the expression of *mcr-1* in *E. coli* ST131-H30 does not affect  
1112 the functionality of the human immune system, nor does it not aid the strain via immune  
1113 evasion. The authors thereafter suggested the use of antibodies targeting the LPS's O-antigen  
1114 as an alternative strategy to combatting MDR infections against *mcr-1* positive isolates<sup>182</sup>.

1115 Other novel compounds produced to manage *mcr*-producing isolates are antisense agents  
1116 with antimicrobial properties; this include phosphorodiamidate morpholino oligomers  
1117 (PPMOs) and peptide nucleic acids (PNAs)<sup>183</sup>. These antisense molecules are designed to  
1118 target mRNA, prevent translation, and restore antimicrobial sensitivity. Daly *et al.* (2017)<sup>184</sup>  
1119 designed peptide-conjugated PPMOs targeted to *mcr-1* mRNA (MCR-1 PPMO) of clinical  
1120 *mcr-1*-positive *E. coli* strains and showed that these molecules were able to make the strains  
1121 re-sensitive to polymyxins by *MCR-1* inhibition<sup>184</sup>. Similar results were achieved by Nezhadi  
1122 *et al.* (2019)<sup>183</sup> with PNAs, designed for inhibition of *mcr-1* translation. They<sup>183</sup> showed that  
1123 the introduction of PNA resulted in a 95% reduction of *mcr-1* expression, measured by RT-  
1124 PCR, highlighting the efficacy of PNAs<sup>183</sup>. Daly *et al.* (2017)<sup>184</sup> evaluated the antisense

1125 approach in a sepsis model using mice and found that a combined therapy of MCR-1 PPMO  
1126 with colistin reduced morbidity and bacterial burden in the spleen at 24hr. Thus, antisense  
1127 agents may be effective therapeutics, either alone by targeting an essential gene resulting in  
1128 cell death,<sup>184</sup> or in combination with colistin<sup>183, 184</sup> to treat *mcr-1*-producing isolates.  
1129 However, these molecules have varying toxicity effects and more *in-vivo* research is required  
1130 prior to clinical application<sup>183</sup>.

### 1131 *Natural compounds*

1132 Other novel compounds that have been reported to restore susceptibility of polymyxins in  
1133 *mcr-1* producing isolates includes the novel *MCR-1* inhibitor, Osthole (7-methoxy-8-(3-  
1134 methyl-2-buteryl) coumarin. Osthole (OST) is a natural compound derived from the dried  
1135 root and rhizome of *Cnidium monnieri*<sup>185</sup>. Zhou *et al.* (2019)<sup>185</sup> evaluated the effects of  
1136 OST on the inhibition of *MCR-1* enzyme and the mechanisms behind the inhibition. The  
1137 colistin-OST combination had a synergistic effect as a mouse-thigh-infection model showed  
1138 that the combination exhibits a bactericidal activity against *mcr-1*-producing  
1139 *Enterobacteriaceae*, significantly reducing the bacterial load in the thighs following  
1140 subcutaneous administration<sup>185</sup>. Using a molecular dynamic stimulation, Zhao *et al.* (2019)  
1141<sup>185</sup> found that OST could localize in the binding pocket (residue 330-350) of MCR-1,  
1142 blocking the substrate and reducing MCR-1's biological activity. OST therefore inhibits  
1143 MCR-1 in *Enterobacteriaceae*, making colistin potent<sup>185</sup>. Due to the conservation of MCR  
1144 proteins, OST may have the same inhibition efficiency across the other MCR variants.

1145 Natural/organic compounds identified with a synergistic effect on colistin include Honokiol  
1146<sup>186</sup>, Isoalantolactone (IAL)<sup>187</sup>, Calycosin<sup>188</sup> and Eugenol<sup>189</sup>. Honokiol was derived from the  
1147 dry skin and bark of *Magnolia officinalis*<sup>186</sup>, IAL is the main sesquiterpene lactone from  
1148 *Radix inulae* and other plants<sup>187</sup>, Calycosin is a flavonoid from a direct root extract of the  
1149 traditional Chinese medicinal herb, *Radix astragali*.<sup>188</sup> Lastly, Eugenol is a phenylpropanoid,  
1150 an essential oil isolated from plants<sup>190</sup>. Each of these compounds, when combined with  
1151 colistin, decreased colistin MICs and increased colistin's bactericidal activity against colistin-  
1152 resistant isolates. Eugenol decreased the expression of *mcr-1*<sup>189</sup> and honokiol bound directly  
1153 to the active site of MCR-1, inhibiting its activity<sup>186</sup>. Guo *et al.* (2020)<sup>186</sup> and Liu *et al.*  
1154 (2020)<sup>188</sup> showed that the natural compounds, honokiol and calycosin, in combinations with  
1155 colistin, respectively reduced the load of bacteria and improved viability in animal models.

1156 *Efflux pump inhibitors*

1157 Efflux pumps play a role in reducing colistin susceptibility in *Enterobacteriaceae*<sup>10</sup>. Baron *et*  
1158 *al.* (2018)<sup>191</sup> found that an efflux pump inhibitor, carbonyl cyanide 3-chlorophenylhydrazone  
1159 (CCCP), was a good alternative to reverse colistin resistance in colistin-resistant isolates  
1160 irrespective of their molecular resistance mechanisms. The study shows that CCCP was able  
1161 to restore colistin activity across a diverse set of strains carrying different colistin resistance  
1162 mechanisms (*mcr-1*, *pmrAB*, *mgrB*, etc)<sup>191, 192</sup>. In *mcr-1* producing isolates, it was seen that  
1163 colistin-CCCP combination inhibited the transcription of the *mcr-1* gene. The mechanism  
1164 behind this observation, however, is unknown<sup>191</sup>.

1165 *FDA-approved drugs*

1166 The food and drug administration (FDA) has a library of FDA-approved drugs that can be  
1167 screened for bactericidal activity on *mcr*-producing *Enterobacteriaceae* isolates (Prestwick  
1168 Chemical, Illkirch-Graffenstuden, France). Multiple compounds such as pentamidine,  
1169 zidovudine<sup>193</sup>, sulphonamide compounds<sup>193</sup>, a polymyxin derivative, NAB739,<sup>194</sup> and  
1170 compound PFK-185,<sup>194</sup> have been identified during a library search.

1171 Zidovudine is a nucleoside reverse transcriptase inhibitor. In the 1980s, it was used as an  
1172 anticancer drug<sup>195</sup>. In 1986, its antibacterial effect was revealed<sup>196</sup> and in 1987, it was used  
1173 as the first antiretroviral for treatment against HIV infections<sup>195, 197</sup>. Peyclit *et al.* (2018)<sup>197</sup>  
1174 investigated the antibacterial activity of Zidovudine against a large number of characterised  
1175 MDR *Enterobacteriaceae* strains isolated from different geographical areas, including  
1176 carbapenem- and colistin-resistant isolates; Zidovudine was effective against  
1177 *Enterobacteriaceae*. Despite their antimicrobial susceptibility profile, the MIC values ranged  
1178 between 0.05-1.67 µg/mL<sup>197</sup>.

1179 Another antiretroviral drug that is used to treat HIV/AIDS but also has bactericidal activity  
1180 against Gram-negative bacteria is Azidothymidine (AZT). Hu *et al.* (2019)<sup>198</sup> shows that  
1181 AZT, in combination with colistin, was able to eradicate MDR *Enterobacteriaceae* strains  
1182 with different antimicrobial susceptibility profiles and enhance the activity of colistin. The  
1183 combined therapy was also effective therapeutically in a murine peritoneal infection against  
1184 NDM-1-producing *K. pneumoniae* and MPEC<sup>198</sup>.

1185 Further, Pentamidine is an antiprotozoal drug that Stokes *et al.* (2017)<sup>199</sup> identified as an  
1186 effective antibiotic adjuvant producing synergistic combination activity against a wide range  
1187 of Gram-negative bacteria. The adjuvant was identified during a library screening of non-

1188 lethal, outer membrane-active compounds<sup>199</sup>. The study shows that Pentamidine directly  
1189 associates with the outer membrane by inhibiting the oligosaccharide (OS) core biosynthesis,  
1190 releasing LPS from the outer membrane<sup>199</sup>. Stokes *et al.* (2017)<sup>199</sup> further showed that  
1191 Pentamidine has synergistic activity with hydrophobic antibiotics such as rifampicin,  
1192 novobiocin, and erythromycin but not with hydrophilic and low-molecular weight antibiotics  
1193<sup>199</sup>. Although the study does not evaluate synergistic combinations with Pentamidine, Stokes  
1194 *et al.* (2017)<sup>199</sup> concluded that pentamidine can be used as an antibiotic adjuvant for treating  
1195 colistin-resistant infections.

1196 Barker *et al.* (2017)<sup>200</sup> screened a diverse cohort of adjuvants to identify a compound that  
1197 could both sensitise colistin-resistant and hypersensitise colistin-susceptible bacteria to  
1198 colistin, to potentially lower the effective dosage of colistin, reducing its toxicity. The study  
1199 identified three compounds that were potent modulators of colistin resistance and were able  
1200 to significantly reduce MIC values in both plasmid- and chromosomal-mediated resistance  
1201 mechanisms, and further hypersensitize colistin-susceptible isolates<sup>200</sup>

1202 Another compound identified in the FDA-approved library with synergistic activity with  
1203 colistin is sulfadiazine (SDI), a sulphonamide compound. Okdah *et al.* (2018)<sup>193</sup> evaluated  
1204 the potential of different sulphonamide compounds with potential synergistic and bactericidal  
1205 activity in combination with colistin; SDI had the highest synergistic effect. The combination  
1206 of SDI-colistin was effective, independent of colistin resistance mechanism, across the broad  
1207 range of MDR bacterium strains tested<sup>193</sup>.

1208 Zhang *et al.* (2019)<sup>194</sup> identified an antitumor drug, PFK-185 and its analogs, PFK-015 and  
1209 3PO, during a screening of the clinical compound library. These compounds can exert  
1210 synergise with colistin against colistin-resistant *Enterobacteriaceae* despite *mcr* expression  
1211 and the antimicrobial susceptibility profile<sup>194</sup>. Zhang *et al.* (2019)<sup>194</sup> found that PFK-185  
1212 had no effect on cellular morphology when used alone. However, when in combination with  
1213 colistin, it enhanced the bacterium-killing effect of colistin, increasing the survival rate to  
1214 60%. The combined colistin-PFK-158 therapy had the most significant bactericidal activity,  
1215 with the most significant reductions in the bacterial burdens post-*in vivo* experiments and  
1216 during time-kills studies.<sup>194</sup>

1217 The last compound reported from the FDA-approved library is a novel polymyxin derivative,  
1218 NAB739, which carries only three of the five amino groups of colistin, each placed in a  
1219 strategic position<sup>201</sup>. Tyrrell *et al.* (2019)<sup>201</sup> showed that NAB739 sensitizes polymyxin-

1220 resistant strains to rifampicin and a combination of the two was synergistic against ten of the  
1221 eleven colistin-resistant strains. Tyrrell *et al.* (2019)<sup>201</sup> further showed that NAB739 was also  
1222 synergistic with meropenem and retapamulin. As well, NAB739 in combination with other  
1223 compounds has significant bactericidal activity against polymyxin-resistant isolates and  
1224 compared to polymyxins, it has a better tolerability and efficacy<sup>201</sup>. Thus, NAB739  
1225 combination therapies may replace polymyxin for treating MDR pathogens<sup>201</sup>.

1226 These studies<sup>197, 199</sup> however, show that old antimicrobials listed within the FDA-approved  
1227 library may be re-introduced against bacteria that are resistant to multiple antibacterials in  
1228 current use<sup>197</sup>.

### 1229 *Combination therapy*

1230 There are multiple compounds, either antibiotics or adjuvants, which are synergistic with  
1231 colistin, thus reducing the dosage of colistin required for treatment, minimizing its toxicity,  
1232 overcoming colistin resistance, and retaining maximal therapeutic efficacy<sup>198, 200</sup>. Colistin  
1233 activity has been restored when it is combined with antibiotics such as rifampicin<sup>202, 203</sup>,  
1234 rifabutin, minocycline<sup>203</sup>, amikacin<sup>204</sup>, tigecycline<sup>205</sup> and clarithromycin<sup>206</sup>. In all these  
1235 reports, the antibiotics were ineffective as monotherapy against MPCRE isolates. However,  
1236 in combination with colistin, they resulted in significant bactericidal activity. Yu *et al.* (2019)  
1237<sup>203</sup> found that colistin in combination with rifampicin, rifabutin or minocycline was able to  
1238 eradicate XDR, NDM- and *mcr*- co-producing *E. coli in-vitro* and in mouse models. Other  
1239 combinations that were confirmed effective against *mcr*-1-producing colistin-resistant *E. coli*  
1240 using an animal model include tigecycline-colistin<sup>205</sup>, clarithromycin-colistin<sup>206</sup> and a triple  
1241 combination of colistin-rifampin-azithromycin discovered by Li *et al.* (2018b)<sup>202</sup>. Another  
1242 triple combination therapy that was discovered was colistin-aztreonam-amikacin, which was  
1243 effective against both carbapenemase-producing and *mcr* -1-producing *Enterobacteriaceae*  
1244 isolates<sup>207</sup>.

1245 Lastly, a combination therapy that was effective against both carbapenem- and colistin-  
1246 resistant *Enterobacteriaceae* isolates was the  $\beta$ -lactam- $\beta$ -lactamase inhibitor, imipenem-  
1247 relebactam, combination<sup>208</sup>. This combined therapy was potent against colistin-resistant  
1248 carbapenemase-producing isolates, making it a potential agent against carbapenemase-  
1249 producing *Enterobacteriaceae*; particularly, those that are colistin resistant (irrespective of  
1250 the mechanism of resistance)<sup>208</sup>.

1251 Conclusion

1252 Herein, we show that *mcr* genes are commonly identified in *E. coli*, *K. pneumoniae*, and  
1253 *Salmonella* sp., with clones within these strains being disseminated globally within animals,  
1254 food, the environment, and humans. *Mcr* genes were initially identified in animal samples,  
1255 specifically livestock animals that were treated with colistin as a therapeutic against Gram-  
1256 negative bacterial infections or as a growth promoter. *Mcr* has spread to the environment  
1257 through contaminated but untreated animal faeces used as manure and through contaminated  
1258 food-producing-animals' products on markets. Contact with these colistin-treated livestock or  
1259 their faeces by humans was an identified transmission route. Human specimens currently  
1260 have the highest reports of *mcr* genes due to the multiple routes of transmission from  
1261 livestock, the environment and from food, and the use of colistin as a therapeutic against  
1262 carbapenem-resistant *Enterobacteriaceae* infections. The presence of clones such as *E. coli*  
1263 ST744 or ST101 in all sources, including animals, the environment, food, and humans,  
1264 highlights these transmission routes. This makes *mcr* a concerning antibiotic resistance gene  
1265 of great interest and priority.

1266 Further, *mcr* genes are commonly associated with mobile genetic elements. IS*Ap11* elements  
1267 have facilitated the horizontal transfer of *mcr-1* within cassettes of composite transposons.  
1268 They have been also associated with IncX<sub>4</sub> plasmids, facilitating their horizontal and vertical  
1269 transfer across species, genera and families.

1270 Although the *mcr* variants have different possible progenitors viz., *Moracella* sp., *Aeromonas*  
1271 sp., and *Shewanella* sp. for *mcr-1*, *mcr-3* and *mcr-4*, respectively, the MCR proteins are very  
1272 well conserved. Each of the 10 MCR proteins encodes a two-domain integral membrane  
1273 protein with a C-terminal periplasmic domain and an N-terminal 5'-helix transmembrane  
1274 domain, each MCR protein further encodes the five conserved residues i.e., E248, T286,  
1275 H389, D458, and H359, located within the active site. PEtN transferase activity was found for  
1276 each MCR protein, and each was able to mediate colistin resistance, although *mcr-9*  
1277 expression requires a specific genetic environment to regulate its expression. The  
1278 conservation seen within MCR proteins, allows for the use of similar therapies for the  
1279 management of MCRPE isolates, specifically in the cases of identified MCR-1 inhibitors.  
1280 Research on novel therapeutics is well-summarised in this review, with techniques such as  
1281 CRISPR-Cas9, peptide nucleic acids, and antimicrobial peptides, which eliminate *mcr* genes  
1282 within the host. Other novel therapeutics were identified by reviving old FDA-approved  
1283 drugs. Some were effective against *mcr*-producing isolates or were synergistic with colistin.



1284 These therapeutics, however, need to be further evaluated for their toxicity in humans. This  
1285 will aid in alleviating the threat imposed by MCRPE in the public health sector

1286 **Funding:** This work was funded by a grant from the National Health Laboratory Service  
1287 (NHLS) given to Dr. John Osei Sekyere under grant number GRANT004 94809 (reference  
1288 number PR2010486).

1289 **Acknowledgements:** None

1290 **Transparency declaration:** None

1291

## 1292 References

- 1293 1. Falagas, M.E., Kasiakou, S.K. & Saravolatz, L.D. Colistin: the revival of polymyxins for the  
1294 management of multidrug-resistant gram-negative bacterial infections. *Clinical infectious*  
1295 *diseases* **40**, 1333-1341 (2005).
- 1296 2. Nigam, A., Kumari, A., Jain, R. & Batra, S. Colistin neurotoxicity: revisited. *Case Reports* **2015**,  
1297 bcr2015210787 (2015).
- 1298 3. Ye, H. *et al.* Diversified mcr-1-harboring plasmid reservoirs confer resistance to colistin in  
1299 human gut microbiota. *MBio* **7**, e00177-00116 (2016).
- 1300 4. Al Atya, A.K. *et al.* Effects of colistin and bacteriocins combinations on the in vitro growth of  
1301 *Escherichia coli* strains from swine origin. *Probiotics and antimicrobial proteins* **8**, 183-190  
1302 (2016).
- 1303 5. (!!! INVALID CITATION !!! (Bulman *et al.*, 2017)).
- 1304 6. Fyfe, C. *et al.* Eravacycline is active against bacterial isolates expressing the polymyxin  
1305 resistance gene mcr-1. *Antimicrobial agents and chemotherapy* **60**, 6989-6990 (2016).
- 1306 7. Paterson, D.L. & Harris, P.N. Colistin resistance: a major breach in our last line of defence.  
1307 *The Lancet. Infectious diseases* **16**, 132-133 (2016).
- 1308 8. Gunn, J.S. The *Salmonella* PmrAB regulon: lipopolysaccharide modifications, antimicrobial  
1309 peptide resistance and more. *Trends in microbiology* **16**, 284-290 (2008).
- 1310 9. Cannatelli, A. *et al.* In vivo emergence of colistin resistance in *Klebsiella pneumoniae*  
1311 producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP  
1312 mgrB regulator. *Antimicrobial agents and chemotherapy* **57**, 5521-5526 (2013).
- 1313 10. Mmatli, M., Mbelle, N.M., Maningi, N.E. & Osei Sekyere, J. Emerging Transcriptional and  
1314 Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance in  
1315 Enterobacteriaceae: a Systematic Review of Current Reports. *Msystems* **5**, e00783-00720  
1316 (2020).
- 1317 11. Liu, Y.Y. *et al.* Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in  
1318 animals and human beings in China: a microbiological and molecular biological study. *Lancet*  
1319 *Infect Dis* **16**, 161-168 (2016).
- 1320 12. Hu, Y., Liu, F., Lin, I.Y., Gao, G.F. & Zhu, B. Dissemination of the mcr-1 colistin resistance  
1321 gene. *Lancet Infect Dis* **16**, 146-147 (2016).
- 1322 13. Hu, M. *et al.* Crystal Structure of *Escherichia coli* originated MCR-1, a phosphoethanolamine  
1323 transferase for Colistin Resistance. *Sci Rep* **6**, 38793 (2016).
- 1324 14. Fage, C.D., Brown, D.B., Boll, J.M., Keatinge-Clay, A.T. & Trent, M.S. Crystallographic study of  
1325 the phosphoethanolamine transferase EptC required for polymyxin resistance and motility in

- 1326            *Campylobacter jejuni*. *Acta crystallographica. Section D, Biological crystallography* **70**, 2730-  
1327            2739 (2014).
- 1328    15.    Wanty, C. *et al.* The structure of the neisserial lipooligosaccharide phosphoethanolamine  
1329            transferase A (LptA) required for resistance to polymyxin. *Journal of molecular biology* **425**,  
1330            3389-3402 (2013).
- 1331    16.    Xu, Y. *et al.* An Evolutionarily Conserved Mechanism for Intrinsic and Transferable Polymyxin  
1332            Resistance. *mBio* **9** (2018).
- 1333    17.    Rebelo, A.R. *et al.* Multiplex PCR for detection of plasmid-mediated colistin resistance  
1334            determinants, *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4* and *mcr-5* for surveillance purposes. *Euro Surveill*  
1335            **23** (2018).
- 1336    18.    Roer, L. *et al.* Novel *mcr-3* variant, encoding mobile colistin resistance, in an ST131  
1337            *Escherichia coli* isolate from bloodstream infection, Denmark, 2014. *Euro Surveill* **22** (2017).
- 1338    19.    Yang, Y.Q. *et al.* Colistin Resistance Gene *mcr-1* and Its Variant in *Escherichia coli* Isolates  
1339            from Chickens in China. *Antimicrob Agents Chemother* **61** (2017).
- 1340    20.    Xavier, B.B. *et al.* Identification of a novel plasmid-mediated colistin-resistance gene, *mcr-2*,  
1341            in *Escherichia coli*, Belgium, June 2016. *Euro Surveill* **21** (2016).
- 1342    21.    Wang, Y. *et al.* Changes in colistin resistance and *mcr-1* abundance in *Escherichia coli* of  
1343            animal and human origins following the ban of colistin-positive additives in China: an  
1344            epidemiological comparative study. *Lancet Infect Dis* **20**, 1161-1171 (2020).
- 1345    22.    Di Pilato, V. *et al.* *mcr-1.2*, a New *mcr* Variant Carried on a Transferable Plasmid from a  
1346            Colistin-Resistant KPC Carbapenemase-Producing *Klebsiella pneumoniae* Strain of Sequence  
1347            Type 512. *Antimicrob Agents Chemother* **60**, 5612-5615 (2016).
- 1348    23.    Anjum, M.F. *et al.* Colistin resistance in *Salmonella* and *Escherichia coli* isolates from a pig  
1349            farm in Great Britain. *J Antimicrob Chemother* **71**, 2306-2313 (2016).
- 1350    24.    Hsu, L.Y. *et al.* Carbapenem-Resistant *Acinetobacter baumannii* and Enterobacteriaceae in  
1351            South and Southeast Asia. *Clin Microbiol Rev* **30**, 1-22 (2017).
- 1352    25.    Snyman, Y. *et al.* Characterisation of *mcr-4.3* in a colistin-resistant *Acinetobacter*  
1353            *nosocomialis* clinical isolate from Cape Town, South Africa. *J Glob Antimicrob Resist* **25**, 102-  
1354            106 (2021).
- 1355    26.    Snesrud, E. *et al.* Chromosomally Encoded *mcr-5* in Colistin-Nonsusceptible *Pseudomonas*  
1356            *aeruginosa*. *Antimicrob Agents Chemother* **62** (2018).
- 1357    27.    Kempf, I., Jouy, E. & Chauvin, C. Colistin use and colistin resistance in bacteria from animals.  
1358            *Int J Antimicrob Agents* **48**, 598-606 (2016).
- 1359    28.    Monte, D.F. *et al.* Chicken Meat as a Reservoir of Colistin-Resistant *Escherichia coli* Strains  
1360            Carrying *mcr-1* Genes in South America. *Antimicrob Agents Chemother* **61** (2017).
- 1361    29.    Runcharoen, C. *et al.* Whole genome sequencing of ESBL-producing *Escherichia coli* isolated  
1362            from patients, farm waste and canals in Thailand. *Genome Med* **9**, 81 (2017).
- 1363    30.    WHO (2011).
- 1364    31.    Collignon, P.C. *et al.* World Health Organization ranking of antimicrobials according to their  
1365            importance in human medicine: a critical step for developing risk management strategies to  
1366            control antimicrobial resistance from food animal production. *Clinical Infectious Diseases* **63**,  
1367            1087-1093 (2016).
- 1368    32.    Sun, J. *et al.* Co-occurrence of *mcr-1* in the chromosome and on an IncHI2 plasmid:  
1369            persistence of colistin resistance in *Escherichia coli*. *Int J Antimicrob Agents* **51**, 842-847  
1370            (2018).
- 1371    33.    Sun, J. *et al.* Deciphering MCR-2 Colistin Resistance. *mBio* **8** (2017).
- 1372    34.    Gomi, R. *et al.* Molecular Characterization of a Multidrug-Resistant IncF Plasmid Carrying  
1373            *mcr-3.1* in an *Escherichia coli* Sequence Type 393 Strain of Wastewater Origin. *Int J*  
1374            *Antimicrob Agents* **54**, 524-526 (2019).
- 1375    35.    Wang, Z., Fu, Y., Du, X.D., Jiang, H. & Wang, Y. Potential transferability of *mcr-3* via IS26-  
1376            mediated homologous recombination in *Escherichia coli*. *Emerg Microbes Infect* **7**, 55 (2018).

- 1377 36. Poirel, L. *et al.* Genetic Features of MCR-1-Producing Colistin-Resistant Escherichia coli  
1378 Isolates in South Africa. *Antimicrob Agents Chemother* **60**, 4394-4397 (2016).
- 1379 37. Poirel, L., Kieffer, N. & Nordmann, P. In vitro study of ISAp1-mediated mobilization of the  
1380 colistin resistance gene mcr-1. *Antimicrobial agents and chemotherapy* **61** (2017).
- 1381 38. Kieffer, N., Nordmann, P. & Poirel, L. Moraxella Species as Potential Sources of MCR-Like  
1382 Polymyxin Resistance Determinants. *Antimicrob Agents Chemother* **61** (2017).
- 1383 39. Poirel, L. *et al.* MCR-2-mediated plasmid-borne polymyxin resistance most likely originates  
1384 from Moraxella pluranimalium. *J Antimicrob Chemother* **72**, 2947-2949 (2017).
- 1385 40. Snesrud, E., McGann, P. & Chandler, M. The Birth and Demise of the ISAp1-mcr-1-ISAp1  
1386 Composite Transposon: the Vehicle for Transferable Colistin Resistance. *mBio* **9**, e02381-  
1387 02317 (2018).
- 1388 41. Li, R. *et al.* Genetic basis of chromosomally-encoded mcr-1 gene. *Int J Antimicrob Agents* **51**,  
1389 578-585 (2018).
- 1390 42. AbuOun, M. *et al.* mcr-1 and mcr-2 variant genes identified in Moraxella species isolated  
1391 from pigs in Great Britain from 2014 to 2015. *J Antimicrob Chemother* **72**, 2745-2749 (2017).
- 1392 43. Stoesser, N., Mathers, A.J., Moore, C.E., Day, N.P. & Crook, D.W. Colistin resistance gene  
1393 mcr-1 and pHNSHP45 plasmid in human isolates of Escherichia coli and Klebsiella  
1394 pneumoniae. *Lancet Infect Dis* **16**, 285-286 (2016).
- 1395 44. Snesrud, E. *et al.* A Model for Transposition of the Colistin Resistance Gene mcr-1 by ISAp1.  
1396 *Antimicrob Agents Chemother* **60**, 6973-6976 (2016).
- 1397 45. Zurfluh, K., Tasara, T., Poirel, L., Nordmann, P. & Stephan, R. Draft Genome Sequence of  
1398 Escherichia coli S51, a Chicken Isolate Harboring a Chromosomally Encoded mcr-1 Gene.  
1399 *Genome Announc* **4** (2016).
- 1400 46. Tegetmeyer, H.E., Jones, S.C., Langford, P.R. & Baltes, N. ISAp1, a novel insertion element of  
1401 Actinobacillus pleuropneumoniae, prevents ApxIV-based serological detection of serotype 7  
1402 strain AP76. *Veterinary microbiology* **128**, 342-353 (2008).
- 1403 47. Szabó, M., Kiss, J., Nagy, Z., Chandler, M. & Olsz, F. Sub-terminal sequences modulating IS30  
1404 transposition in vivo and in vitro. *Journal of molecular biology* **375**, 337-352 (2008).
- 1405 48. Wang, Q. *et al.* Phenotypic and Genotypic Characterization of Carbapenem-resistant  
1406 Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016).  
1407 *Clin Infect Dis* **67**, S196-s205 (2018).
- 1408 49. Snesrud, E. *et al.* Analysis of Serial Isolates of mcr-1-Positive Escherichia coli Reveals a Highly  
1409 Active ISAp1 Transposon. *Antimicrob Agents Chemother* **61** (2017).
- 1410 50. Zhao, F., Feng, Y., Lü, X., McNally, A. & Zong, Z. IncP Plasmid Carrying Colistin Resistance  
1411 Gene mcr-1 in Klebsiella pneumoniae from Hospital Sewage. *Antimicrob Agents Chemother*  
1412 **61** (2017).
- 1413 51. Petrillo, M., Angers-Loustau, A. & Kreysa, J. Possible genetic events producing colistin  
1414 resistance gene mcr-1. *Lancet Infect Dis* **16**, 280 (2016).
- 1415 52. Sia, C.M. *et al.* The characterization of mobile colistin resistance (mcr) genes among 33000  
1416 Salmonella enterica genomes from routine public health surveillance in England. *Microb*  
1417 *Genom* **6** (2020).
- 1418 53. Li, R., Chen, K., Chan, E.W. & Chen, S. Characterization of the stability and dynamics of  
1419 Tn6330 in an Escherichia coli strain by nanopore long reads. *J Antimicrob Chemother* **74**,  
1420 1807-1811 (2019).
- 1421 54. Tarabaj, H. *et al.* Plasmid-Mediated mcr-1 Colistin Resistance in Escherichia coli from a Black  
1422 Kite in Russia. *Antimicrob Agents Chemother* **63** (2019).
- 1423 55. Ji, X. *et al.* Dissemination of extended-spectrum  $\beta$ -lactamase-producing Escherichia coli  
1424 carrying mcr-1 among multiple environmental sources in rural China and associated risk to  
1425 human health. *Environ Pollut* **251**, 619-627 (2019).

- 1426 56. Tijet, N. *et al.* Molecular characteristics of mcr-1-carrying plasmids and new mcr-1 variant  
1427 recovered from polyclonal clinical Escherichia coli from Argentina and Canada. *PLoS One* **12**,  
1428 e0180347 (2017).
- 1429 57. Sun, J. *et al.* Genetic Analysis of the IncX4 Plasmids: Implications for a Unique Pattern in the  
1430 mcr-1 Acquisition. *Sci Rep* **7**, 424 (2017).
- 1431 58. Nang, S.C. *et al.* Fitness cost of mcr-1-mediated polymyxin resistance in Klebsiella  
1432 pneumoniae. *J Antimicrob Chemother* **73**, 1604-1610 (2018).
- 1433 59. Li, R. *et al.* Genetic characterization of mcr-1-bearing plasmids to depict molecular  
1434 mechanisms underlying dissemination of the colistin resistance determinant. *J Antimicrob*  
1435 *Chemother* **72**, 393-401 (2017).
- 1436 60. He, T. *et al.* Characterization of NDM-5-positive extensively resistant Escherichia coli isolates  
1437 from dairy cows. *Vet Microbiol* **207**, 153-158 (2017).
- 1438 61. Andersson, D.I. The biological cost of mutational antibiotic resistance: any practical  
1439 conclusions? *Current opinion in microbiology* **9**, 461-465 (2006).
- 1440 62. Cannatelli, A., Santos-Lopez, A., Giani, T., Gonzalez-Zorn, B. & Rossolini, G.M. Polymyxin  
1441 resistance caused by mgrB inactivation is not associated with significant biological cost in  
1442 Klebsiella pneumoniae. *Antimicrobial agents and chemotherapy* **59**, 2898-2900 (2015).
- 1443 63. Giordano, C. *et al.* Reduced Fitness Costs of mcr-1.2 Compared to Mutated pmrB in Isogenic  
1444 Colistin-Resistant KPC-3-Producing Klebsiella pneumoniae. *mSphere* **4** (2019).
- 1445 64. Phan, M.-D. *et al.* Modifications in the pmrB gene are the primary mechanism for the  
1446 development of chromosomally encoded resistance to polymyxins in uropathogenic  
1447 Escherichia coli. *Journal of Antimicrobial Chemotherapy* **72**, 2729-2736 (2017).
- 1448 65. Cannatelli, A. *et al.* An allelic variant of the PmrB sensor kinase responsible for colistin  
1449 resistance in an Escherichia coli strain of clinical origin. *Sci Rep* **7**, 5071 (2017).
- 1450 66. Cheng, Y.-H., Lin, T.-L., Lin, Y.-T. & Wang, J.-T. Amino acid substitutions of CrrB responsible  
1451 for resistance to colistin through CrrC in Klebsiella pneumoniae. *Antimicrobial agents and*  
1452 *chemotherapy* **60**, 3709-3716 (2016).
- 1453 67. Tietgen, M. *et al.* Impact of the colistin resistance gene mcr-1 on bacterial fitness. *Int J*  
1454 *Antimicrob Agents* **51**, 554-561 (2018).
- 1455 68. Wang, R. *et al.* The prevalence of colistin resistance in Escherichia coli and Klebsiella  
1456 pneumoniae isolated from food animals in China: coexistence of mcr-1 and bla(NDM) with  
1457 low fitness cost. *Int J Antimicrob Agents* **51**, 739-744 (2018).
- 1458 69. Zheng, B. *et al.* Complete genome sequencing and genomic characterization of two  
1459 Escherichia coli strains co-producing MCR-1 and NDM-1 from bloodstream infection. *Sci Rep*  
1460 **7**, 17885 (2017).
- 1461 70. Yang, Q. *et al.* Balancing mcr-1 expression and bacterial survival is a delicate equilibrium  
1462 between essential cellular defence mechanisms. *Nat Commun* **8**, 2054 (2017).
- 1463 71. Ma, K., Feng, Y. & Zong, Z. Fitness cost of a mcr-1-carrying IncHI2 plasmid. *PLoS One* **13**,  
1464 e0209706 (2018).
- 1465 72. Dahlberg, C. & Chao, L. Amelioration of the cost of conjugative plasmid carriage in  
1466 Escherichia coli K12. *Genetics* **165**, 1641-1649 (2003).
- 1467 73. Zhang, Y. *et al.* Decreased Fitness and Virulence in ST10 Escherichia coli Harboring bla(NDM-  
1468 5) and mcr-1 against a ST4981 Strain with bla(NDM-5). *Front Cell Infect Microbiol* **7**, 242  
1469 (2017).
- 1470 74. Arcilla, M.S. *et al.* Dissemination of the mcr-1 colistin resistance gene. *Lancet Infect Dis* **16**,  
1471 147-149 (2016).
- 1472 75. Wei, P. *et al.* Substrate analog interaction with MCR-1 offers insight into the rising threat of  
1473 the plasmid-mediated transferable colistin resistance. *Faseb j* **32**, 1085-1098 (2018).
- 1474 76. Liu, Z.-X., Han, Z., Yu, X.-L., Wen, G. & Zeng, C. Crystal structure of the catalytic domain of  
1475 MCR-1 (cMCR-1) in complex with d-Xylose. *Crystals* **8**, 172 (2018).

- 1476 77. Stojanoski, V. *et al.* Structure of the catalytic domain of the colistin resistance enzyme MCR-  
1477 1. *BMC Biol* **14**, 81 (2016).
- 1478 78. Hinchliffe, P. *et al.* Insights into the Mechanistic Basis of Plasmid-Mediated Colistin  
1479 Resistance from Crystal Structures of the Catalytic Domain of MCR-1. *Sci Rep* **7**, 39392  
1480 (2017).
- 1481 79. Gao, R. *et al.* Dissemination and mechanism for the MCR-1 colistin resistance. *PLoS*  
1482 *pathogens* **12**, e1005957 (2016).
- 1483 80. Anandan, A. *et al.* Structure of a lipid A phosphoethanolamine transferase suggests how  
1484 conformational changes govern substrate binding. *Proceedings of the National Academy of*  
1485 *Sciences* **114**, 2218-2223 (2017).
- 1486 81. Xu, Y., Lin, J., Cui, T., Srinivas, S. & Feng, Y. Mechanistic insights into transferable polymyxin  
1487 resistance among gut bacteria. *J Biol Chem* **293**, 4350-4365 (2018).
- 1488 82. Dortet, L. *et al.* Rapid detection and discrimination of chromosome- and MCR-plasmid-  
1489 mediated resistance to polymyxins by MALDI-TOF MS in *Escherichia coli*: the MALDixin test. *J*  
1490 *Antimicrob Chemother* **73**, 3359-3367 (2018).
- 1491 83. Wanty, C. *et al.* The structure of the neisserial lipooligosaccharide phosphoethanolamine  
1492 transferase A (LptA) required for resistance to polymyxin. *J Mol Biol* **425**, 3389-3402 (2013).
- 1493 84. Partridge, S.R. *mcr-2* in the IncX4 plasmid pKP37-BE is flanked by directly oriented copies of  
1494 ISEc69. *J Antimicrob Chemother* **72**, 1533-1535 (2017).
- 1495 85. Garcia-Graells, C. *et al.* Detection of Plasmid-Mediated Colistin Resistance, *mcr-1* and *mcr-2*  
1496 Genes, in *Salmonella* spp. Isolated from Food at Retail in Belgium from 2012 to 2015.  
1497 *Foodborne Pathog Dis* **15**, 114-117 (2018).
- 1498 86. Zhang, J. *et al.* Molecular detection of colistin resistance genes (*mcr-1*, *mcr-2* and *mcr-3*) in  
1499 nasal/oropharyngeal and anal/cloacal swabs from pigs and poultry. *Sci Rep* **8**, 3705 (2018).
- 1500 87. Ghasemian, A. *et al.* Expression of adhesin genes and biofilm formation among *Klebsiella*  
1501 *oxytoca* clinical isolates from patients with antibiotic-associated haemorrhagic colitis. *J Med*  
1502 *Microbiol* **68**, 978-985 (2019).
- 1503 88. Ahmed, Z.S., Elshafiee, E.A., Khalefa, H.S., Kadry, M. & Hamza, D.A. Evidence of colistin  
1504 resistance genes (*mcr-1* and *mcr-2*) in wild birds and its public health implication in Egypt.  
1505 *Antimicrob Resist Infect Control* **8**, 197 (2019).
- 1506 89. Partridge, S.R. *et al.* Proposal for assignment of allele numbers for mobile colistin resistance  
1507 (*mcr*) genes. *J Antimicrob Chemother* **73**, 2625-2630 (2018).
- 1508 90. Yin, W. *et al.* Novel Plasmid-Mediated Colistin Resistance Gene *mcr-3* in *Escherichia coli*.  
1509 *mBio* **8** (2017).
- 1510 91. Kieffer, N. *et al.* Genetic and Functional Characterization of an MCR-3-Like Enzyme-  
1511 Producing *Escherichia coli* Isolate Recovered from Swine in Brazil. *Antimicrob Agents*  
1512 *Chemother* **62** (2018).
- 1513 92. Wang, X. *et al.* Presence of an *mcr-3* Variant in *Aeromonas caviae*, *Proteus mirabilis*, and  
1514 *Escherichia coli* from One Domestic Duck. *Antimicrob Agents Chemother* **62** (2018).
- 1515 93. Long, H. *et al.* The co-transfer of plasmid-borne colistin-resistant genes *mcr-1* and *mcr-3.5*,  
1516 the carbapenemase gene *bla*(NDM-5) and the 16S methylase gene *rmtB* from *Escherichia*  
1517 *coli*. *Sci Rep* **9**, 696 (2019).
- 1518 94. Yang, Q.E. *et al.* Compensatory mutations modulate the competitiveness and dynamics of  
1519 plasmid-mediated colistin resistance in *Escherichia coli* clones. *Isme j* **14**, 861-865 (2020).
- 1520 95. Liu, L., Feng, Y., Zhang, X., McNally, A. & Zong, Z. New Variant of *mcr-3* in an Extensively  
1521 Drug-Resistant *Escherichia coli* Clinical Isolate Carrying *mcr-1* and *bla*(NDM-5). *Antimicrob*  
1522 *Agents Chemother* **61** (2017).
- 1523 96. Creighton, J. *et al.* Co-occurrence of *mcr-1* and *mcr-3* genes in a single *Escherichia coli* in  
1524 New Zealand. *J Antimicrob Chemother* **74**, 3113-3116 (2019).

- 1525 97. Xiang, R. *et al.* Colocation of the Polymyxin Resistance Gene *mcr-1* and a Variant of *mcr-3* on  
1526 a Plasmid in an *Escherichia coli* Isolate from a Chicken Farm. *Antimicrob Agents Chemother*  
1527 **62** (2018).
- 1528 98. Cabello, F.C., Tomova, A., Ivanova, L. & Godfrey, H.P. Aquaculture and *mcr* colistin resistance  
1529 determinants. *MBio* **8**, e01229-01217 (2017).
- 1530 99. Wang, Z. *et al.* Genetic environment of colistin resistance genes *mcr-1* and *mcr-3* in  
1531 *Escherichia coli* from one pig farm in China. *Vet Microbiol* **230**, 56-61 (2019).
- 1532 100. Litrup, E. *et al.* Plasmid-borne colistin resistance gene *mcr-3* in *Salmonella* isolates from  
1533 human infections, Denmark, 2009-17. *Euro Surveill* **22** (2017).
- 1534 101. Carattoli, A. *et al.* Novel plasmid-mediated colistin resistance *mcr-4* gene in *Salmonella* and  
1535 *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill* **22** (2017).
- 1536 102. Chavda, B. *et al.* Co-identification of *mcr-4.3* and *bla*(NDM-1) in a Clinical Enterobacter  
1537 *cloacae* Isolate from China. *Antimicrob Agents Chemother* **62** (2018).
- 1538 103. Carattoli, A., Carretto, E., Brovarone, F., Sarti, M. & Villa, L. Comparative analysis of an *mcr-4*  
1539 *Salmonella enterica* subsp. *enterica* monophasic variant of human and animal origin. *J*  
1540 *Antimicrob Chemother* **73**, 3332-3335 (2018).
- 1541 104. García, V. *et al.* Co-occurrence of *mcr-1*, *mcr-4* and *mcr-5* genes in multidrug-resistant ST10  
1542 Enterotoxigenic and Shiga toxin-producing *Escherichia coli* in Spain (2006-2017). *Int J*  
1543 *Antimicrob Agents* **52**, 104-108 (2018).
- 1544 105. Teo, J.W.P. *et al.* *mcr-3* and *mcr-4* Variants in Carbapenemase-Producing Clinical  
1545 Enterobacteriaceae Do Not Confer Phenotypic Polymyxin Resistance. *J Clin Microbiol* **56**  
1546 (2018).
- 1547 106. Sun, Q. *et al.* *Leclercia adecarboxylata* From Human Gut Flora Carries *mcr-4.3* and *bla* (IMP-  
1548 4)-Bearing Plasmids. *Front Microbiol* **10**, 2805 (2019).
- 1549 107. Borowiak, M. *et al.* Identification of a novel transposon-associated phosphoethanolamine  
1550 transferase gene, *mcr-5*, conferring colistin resistance in d-tartrate fermenting *Salmonella*  
1551 *enterica* subsp. *enterica* serovar Paratyphi B. *J Antimicrob Chemother* **72**, 3317-3324 (2017).
- 1552 108. Fleres, G. *et al.* Detection of a novel *mcr-5.4* gene variant in hospital tap water by shotgun  
1553 metagenomic sequencing. *J Antimicrob Chemother* **74**, 3626-3628 (2019).
- 1554 109. Guo, S. *et al.* Conjugative IncX1 Plasmid Harboring Colistin Resistance Gene *mcr-5.1* in  
1555 *Escherichia coli* Isolated from Chicken Rice Retailed in Singapore. *Antimicrob Agents*  
1556 *Chemother* **63** (2019).
- 1557 110. Borowiak, M. *et al.* Characterization of *mcr-5*-Harboring *Salmonella enterica* subsp. *enterica*  
1558 Serovar Typhimurium Isolates from Animal and Food Origin in Germany. *Antimicrob Agents*  
1559 *Chemother* **63** (2019).
- 1560 111. Kieffer, N., Nordmann, P., Millemann, Y. & Poirel, L. Functional Characterization of a  
1561 Miniature Inverted Transposable Element at the Origin of *mcr-5* Gene Acquisition in  
1562 *Escherichia coli*. *Antimicrob Agents Chemother* **63** (2019).
- 1563 112. Hammerl, J.A. *et al.* *mcr-5* and a novel *mcr-5.2* variant in *Escherichia coli* isolates from food  
1564 and food-producing animals, Germany, 2010 to 2017. *J Antimicrob Chemother* **73**, 1433-1435  
1565 (2018).
- 1566 113. Ma, S. *et al.* Mobile colistin resistance gene *mcr-5* in porcine *Aeromonas hydrophila*. *J*  
1567 *Antimicrob Chemother* **73**, 1777-1780 (2018).
- 1568 114. Yang, Y.Q., Li, Y.X., Lei, C.W., Zhang, A.Y. & Wang, H.N. Novel plasmid-mediated colistin  
1569 resistance gene *mcr-7.1* in *Klebsiella pneumoniae*. *J Antimicrob Chemother* **73**, 1791-1795  
1570 (2018).
- 1571 115. Furlan, J.P.R. *et al.* Occurrence of clinically relevant antimicrobial resistance genes, including  
1572 *mcr-3* and *mcr-7.1*, in soil and water from a recreation club. *International Journal of*  
1573 *Environmental Health Research*, 1-10 (2020).

- 1574 116. Furlan, J.P.R. *et al.* Occurrence and abundance of clinically relevant antimicrobial resistance  
1575 genes in environmental samples after the Brumadinho dam disaster, Brazil. *Science of The*  
1576 *Total Environment* **726**, 138100 (2020).
- 1577 117. Dos Santos, L.D.R. *et al.* Co-occurrence of mcr-1, mcr-3, mcr-7 and clinically relevant  
1578 antimicrobial resistance genes in environmental and fecal samples. *Archives of microbiology*  
1579 **202**, 1795-1800 (2020).
- 1580 118. Wang, X. *et al.* Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-  
1581 producing *Klebsiella pneumoniae*. *Emerg Microbes Infect* **7**, 122 (2018).
- 1582 119. Wang, X. *et al.* Emergence of Colistin Resistance Gene mcr-8 and Its Variant in *Raoultella*  
1583 *ornithinolytica*. *Front Microbiol* **10**, 228 (2019).
- 1584 120. Bonnin, R.A., Bernabeu, S., Jauregui, F., Naas, T. & Dortet, L. MCR-8 mediated colistin  
1585 resistance in a carbapenem-resistant *Klebsiella pneumoniae* isolated from a repatriated  
1586 patient from Morocco. *Int J Antimicrob Agents* **55**, 105920 (2020).
- 1587 121. Wu, B. *et al.* Heterogeneity and Diversity of mcr-8 Genetic Context in Chicken-Associated  
1588 *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* **65** (2020).
- 1589 122. Yang, X., Liu, L., Wang, Z., Bai, L. & Li, R. Emergence of mcr-8.2-bearing *Klebsiella*  
1590 *quasipneumoniae* of animal origin. *J Antimicrob Chemother* **74**, 2814-2817 (2019).
- 1591 123. Sun, S. *et al.* Co-existence of a novel plasmid-mediated efflux pump with colistin resistance  
1592 gene mcr in one plasmid confers transferable multidrug resistance in *Klebsiella pneumoniae*.  
1593 *Emerg Microbes Infect* **9**, 1102-1113 (2020).
- 1594 124. Salloum, T. *et al.* First report of plasmid-mediated colistin resistance mcr-8.1 gene from a  
1595 clinical *Klebsiella pneumoniae* isolate from Lebanon. *Antimicrob Resist Infect Control* **9**, 94  
1596 (2020).
- 1597 125. Ngbede, E.O. *et al.* Identification of mobile colistin resistance genes (mcr-1.1, mcr-5 and mcr-  
1598 8.1) in Enterobacteriaceae and *Alcaligenes faecalis* of human and animal origin, Nigeria. *Int J*  
1599 *Antimicrob Agents* **56**, 106108 (2020).
- 1600 126. Nabti, L.Z. *et al.* Development of real-time PCR assay allowed describing the first clinical  
1601 *Klebsiella pneumoniae* isolate harboring plasmid-mediated colistin resistance mcr-8 gene in  
1602 Algeria. *J Glob Antimicrob Resist* **20**, 266-271 (2020).
- 1603 127. Carroll, L.M. *et al.* Identification of Novel Mobilized Colistin Resistance Gene mcr-9 in a  
1604 Multidrug-Resistant, Colistin-Susceptible *Salmonella enterica* Serotype Typhimurium Isolate.  
1605 *mBio* **10** (2019).
- 1606 128. Börjesson, S. *et al.* A link between the newly described colistin resistance gene mcr-9 and  
1607 clinical Enterobacteriaceae isolates carrying bla(SHV-12) from horses in Sweden. *J Glob*  
1608 *Antimicrob Resist* **20**, 285-289 (2020).
- 1609 129. Chavda, K.D. *et al.* First Report of bla (VIM-4)- and mcr-9-Coharboring Enterobacter Species  
1610 Isolated from a Pediatric Patient. *mSphere* **4** (2019).
- 1611 130. Kananzadeh, P. *et al.* Emergence of carbapenem-resistant and colistin-susceptible  
1612 *Enterobacter cloacae* complex co-harboring bla(IMP-1) and mcr-9 in Japan. *BMC Infect Dis*  
1613 **20**, 282 (2020).
- 1614 131. Osei Sekyere, J., Maningi, N.E., Modipane, L. & Mbelle, N.M. Emergence of mcr-9.1 in  
1615 Extended-Spectrum- $\beta$ -Lactamase-Producing Clinical Enterobacteriaceae in Pretoria, South  
1616 Africa: Global Evolutionary Phylogenomics, Resistome, and Mobilome. *mSystems* **5** (2020).
- 1617 132. Ding, M. *et al.* Co-infections of two carbapenemase-producing *Enterobacter hormaechei*  
1618 clinical strains isolated from the same diabetes individual in China. *J Med Microbiol* **70**  
1619 (2021).
- 1620 133. Lin, M. *et al.* Co-Occurrence of mcr-9 and bla (NDM-1) in *Enterobacter cloacae* Isolated from  
1621 a Patient with Bloodstream Infection. *Infect Drug Resist* **13**, 1397-1402 (2020).
- 1622 134. Ribeiro, T.G. *et al.* *Citrobacter telavivum* sp. nov. with chromosomal mcr-9 from hospitalized  
1623 patients. *Eur J Clin Microbiol Infect Dis* **40**, 123-131 (2021).


- 1624 135. Yuan, Y. *et al.* Coproduction Of MCR-9 And NDM-1 By Colistin-Resistant Enterobacter  
1625 hormaechei Isolated From Bloodstream Infection. *Infect Drug Resist* **12**, 2979-2985 (2019).
- 1626 136. Khanawapee, A. *et al.* Distribution and Molecular Characterization of Escherichia coli  
1627 Harboring mcr Genes Isolated from Slaughtered Pigs in Thailand. *Microb Drug Resist* **27**, 971-  
1628 979 (2021).
- 1629 137. Cha, M.H. *et al.* Emergence of Transferable mcr-9 Gene-Carrying Colistin-Resistant  
1630 Salmonella enterica Dessau ST14 Isolated from Retail Chicken Meat in Korea. *Foodborne*  
1631 *Pathog Dis* **17**, 720-727 (2020).
- 1632 138. Tyson, G.H. *et al.* The mcr-9 Gene of Salmonella and Escherichia coli Is Not Associated with  
1633 Colistin Resistance in the United States. *Antimicrob Agents Chemother* **64** (2020).
- 1634 139. Li, Y. *et al.* Characterization of the global distribution and diversified plasmid reservoirs of  
1635 the colistin resistance gene mcr-9. *Sci Rep* **10**, 8113 (2020).
- 1636 140. Kieffer, N. *et al.* mcr-9, an Inducible Gene Encoding an Acquired Phosphoethanolamine  
1637 Transferase in Escherichia coli, and Its Origin. *Antimicrob Agents Chemother* **63** (2019).
- 1638 141. Wang, C. *et al.* Identification of novel mobile colistin resistance gene mcr-10. *Emerg*  
1639 *Microbes Infect* **9**, 508-516 (2020).
- 1640 142. Xu, T. *et al.* Identification of mcr-10 carried by self-transmissible plasmids and chromosome  
1641 in Enterobacter roggkampii strains isolated from hospital sewage water. *Environ Pollut*  
1642 **268**, 115706 (2021).
- 1643 143. Yang, J. *et al.* Potential Mobilization of mcr-10 by an Integrative Mobile Element via Site-  
1644 Specific Recombination in Cronobacter sakazakii. *Antimicrob Agents Chemother* **65** (2021).
- 1645 144. Sato, T. *et al.* Complete Genome Sequence of an mcr-10-Possessing Enterobacter  
1646 roggkampii Strain Isolated from a Dog in Japan. *Microbiology Resource Announcements*  
1647 **10**, e00426-00421 (2021).
- 1648 145. Lei, C.W., Zhang, Y., Wang, Y.T. & Wang, H.N. Detection of Mobile Colistin Resistance Gene  
1649 mcr-10.1 in a Conjugative Plasmid from Enterobacter roggkampii of Chicken Origin in  
1650 China. *Antimicrob Agents Chemother* **64** (2020).
- 1651 146. Nguyen, N.T. *et al.* Use of Colistin and Other Critical Antimicrobials on Pig and Chicken Farms  
1652 in Southern Vietnam and Its Association with Resistance in Commensal Escherichia coli  
1653 Bacteria. *Appl Environ Microbiol* **82**, 3727-3735 (2016).
- 1654 147. Carrique-Mas, J.J. *et al.* Antimicrobial usage in chicken production in the Mekong Delta of  
1655 Vietnam. *Zoonoses and public health* **62**, 70-78 (2015).
- 1656 148. Monte, D.F. *et al.* Chicken meat as a reservoir of colistin-resistant Escherichia coli strains  
1657 carrying mcr-1 genes in South America. *Antimicrobial agents and chemotherapy* **61** (2017).
- 1658 149. Clemente, L. *et al.* Revealing mcr-1-positive ESBL-producing Escherichia coli strains among  
1659 Enterobacteriaceae from food-producing animals (bovine, swine and poultry) and meat  
1660 (bovine and swine), Portugal, 2010-2015. *Int J Food Microbiol* **296**, 37-42 (2019).
- 1661 150. Shen, Y. *et al.* Anthropogenic and environmental factors associated with high incidence of  
1662 mcr-1 carriage in humans across China. *Nat Microbiol* **3**, 1054-1062 (2018).
- 1663 151. Trung, N.V. *et al.* Zoonotic Transmission of mcr-1 Colistin Resistance Gene from Small-Scale  
1664 Poultry Farms, Vietnam. *Emerg Infect Dis* **23**, 529-532 (2017).
- 1665 152. Hille, K. *et al.* Investigation of potential risk factors for the occurrence of Escherichia coli  
1666 isolates from German fattening pig farms harbouring the mcr-1 colistin-resistance gene. *Int J*  
1667 *Antimicrob Agents* **51**, 177-180 (2018).
- 1668 153. Xia, X. *et al.* Association of colistin residues and manure treatment with the abundance of  
1669 mcr-1 gene in swine feedlots. *Environ Int* **127**, 361-370 (2019).
- 1670 154. Luo, J. *et al.* Emergence of mcr-1 in Raoultella ornithinolytica and Escherichia coli Isolates  
1671 from Retail Vegetables in China. *Antimicrob Agents Chemother* **61** (2017).
- 1672 155. Shen, Y. *et al.* Integrated aquaculture contributes to the transfer of mcr-1 between animals  
1673 and humans via the aquaculture supply chain. *Environ Int* **130**, 104708 (2019).



- 1674 156. Yang, Q.E. *et al.* Environmental dissemination of mcr-1 positive Enterobacteriaceae by  
1675 Chrysomya spp. (common blowfly): An increasing public health risk. *Environ Int* **122**, 281-290  
1676 (2019).
- 1677 157. Agnoletti, F., Brunetta, R., Bano, L., Drigo, I. & Mazzolini, E. Longitudinal study on  
1678 antimicrobial consumption and resistance in rabbit farming. *Int J Antimicrob Agents* **51**, 197-  
1679 205 (2018).
- 1680 158. Malhotra-Kumar, S. *et al.* Colistin-resistant Escherichia coli harbouring mcr-1 isolated from  
1681 food animals in Hanoi, Vietnam. *Lancet Infect Dis* **16**, 286-287 (2016).
- 1682 159. World Health Organization Stop using antibiotics in healthy animals to prevent the spread of  
1683 antibiotic resistance. *World Health Organization Media Center*. [http://www.who.  
1684 int/mediacentre/news/releases/2017/antibiotics-animalseffectiveness/en](http://www.who.int/mediacentre/news/releases/2017/antibiotics-animalseffectiveness/en) (2017).
- 1685 160. Randall, L.P. *et al.* Longitudinal study on the occurrence in pigs of colistin-resistant  
1686 Escherichia coli carrying mcr-1 following the cessation of use of colistin. *J Appl Microbiol* **125**,  
1687 596-608 (2018).
- 1688 161. Haenni, M., Métayer, V., Gay, E. & Madec, J.Y. Increasing Trends in mcr-1 Prevalence among  
1689 Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates from French Calves  
1690 despite Decreasing Exposure to Colistin. *Antimicrob Agents Chemother* **60**, 6433-6434  
1691 (2016).
- 1692 162. Skov, R.L. & Monnet, D.L. Plasmid-mediated colistin resistance (mcr-1 gene): three months  
1693 later, the story unfolds. *Euro Surveill* **21**, 30155 (2016).
- 1694 163. Yang, Y.Q. *et al.* Co-occurrence of mcr-1 and ESBL on a single plasmid in Salmonella enterica.  
1695 *J Antimicrob Chemother* **71**, 2336-2338 (2016).
- 1696 164. Gröndahl-Yli-Hannuksela, K. *et al.* The first human report of mobile colistin resistance gene,  
1697 mcr-1, in Finland. *Apmis* **126**, 413-417 (2018).
- 1698 165. Henig, O. *et al.* Identification of four patients with colistin-resistant Escherichia coli  
1699 containing the mobile colistin resistance mcr-1 gene from a single health system in  
1700 Michigan. *Infect Control Hosp Epidemiol* **40**, 1059-1062 (2019).
- 1701 166. Wang, Y. *et al.* Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-  
1702 positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological  
1703 and clinical study. *Lancet Infect Dis* **17**, 390-399 (2017).
- 1704 167. Lu, X. *et al.* Epidemiologic and genomic insights on mcr-1-harboring Salmonella from  
1705 diarrhoeal outpatients in Shanghai, China, 2006-2016. *EBioMedicine* **42**, 133-144 (2019).
- 1706 168. Zhang, X.F. *et al.* Possible Transmission of mcr-1-Harboring Escherichia coli between  
1707 Companion Animals and Human. *Emerg Infect Dis* **22**, 1679-1681 (2016).
- 1708 169. Hryhorowicz, M., Lipiński, D., Zeyland, J. & Słomski, R. CRISPR/Cas9 immune system as a tool  
1709 for genome engineering. *Archivum immunologiae et therapiae experimentalis* **65**, 233-240  
1710 (2017).
- 1711 170. Dong, H., Xiang, H., Mu, D., Wang, D. & Wang, T. Exploiting a conjugative CRISPR/Cas9  
1712 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli. *Int J*  
1713 *Antimicrob Agents* **53**, 1-8 (2019).
- 1714 171. Wang, P. *et al.* Eliminating mcr-1-harboring plasmids in clinical isolates using the  
1715 CRISPR/Cas9 system. *J Antimicrob Chemother* **74**, 2559-2565 (2019).
- 1716 172. He, Y.Z. *et al.* A transposon-associated CRISPR/Cas9 system specifically eliminates both  
1717 chromosomal and plasmid-borne mcr-1 in Escherichia coli. *Antimicrob Agents Chemother*,  
1718 Aac0105421 (2021).
- 1719 173. Sun, L. *et al.* Generation of Newly Discovered Resistance Gene mcr-1 Knockout in Escherichia  
1720 coli Using the CRISPR/Cas9 System. *J Microbiol Biotechnol* **27**, 1276-1280 (2017).
- 1721 174. Zhao, C. *et al.* In vitro activities of Eravacycline against 336 isolates collected from 2012 to  
1722 2016 from 11 teaching hospitals in China. *BMC Infect Dis* **19**, 508 (2019).

- 1723 175. Denervaud-Tendon, V., Poirel, L., Connolly, L.E., Krause, K.M. & Nordmann, P. Plazomicin  
1724 activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.  
1725 *J Antimicrob Chemother* **72**, 2787-2791 (2017).
- 1726 176. Gerstmans, H., Rodríguez-Rubio, L., Lavigne, R. & Briers, Y. From endolysins to Artilysin® s:  
1727 novel enzyme-based approaches to kill drug-resistant bacteria. *Biochemical Society*  
1728 *Transactions* **44**, 123-128 (2016).
- 1729 177. Schirmeier, E. *et al.* Inhibitory and bactericidal effect of Artilysin(®) Art-175 against colistin-  
1730 resistant mcr-1-positive Escherichia coli isolates. *Int J Antimicrob Agents* **51**, 528-529 (2018).
- 1731 178. Drider, D., Bendali, F., Naghmouchi, K. & Chikindas, M.L. Bacteriocins: not only antibacterial  
1732 agents. *Probiotics and antimicrobial proteins* **8**, 177-182 (2016).
- 1733 179. van der Weide, H. *et al.* Antimicrobial activity of two novel antimicrobial peptides AA139 and  
1734 SET-M33 against clinically and genotypically diverse Klebsiella pneumoniae isolates with  
1735 differing antibiotic resistance profiles. *International journal of antimicrobial agents* **54**, 159-  
1736 166 (2019).
- 1737 180. Dobias, J., Poirel, L. & Nordmann, P. Cross-resistance to human cationic antimicrobial  
1738 peptides and to polymyxins mediated by the plasmid-encoded MCR-1? *Clin Microbiol Infect*  
1739 **23**, 676.e671-676.e675 (2017).
- 1740 181. Napier, B.A. *et al.* Clinical use of colistin induces cross-resistance to host antimicrobials in  
1741 Acinetobacter baumannii. *MBio* **4**, e00021-00013 (2013).
- 1742 182. Guachalla, L.M. *et al.* Retained Activity of an O25b-Specific Monoclonal Antibody against an  
1743 Mcr-1-Producing Escherichia coli Sequence Type 131 Strain. *Antimicrob Agents Chemother*  
1744 **62** (2018).
- 1745 183. Nezhadi, J. *et al.* Peptide nucleic acid-mediated re-sensitization of colistin resistance  
1746 Escherichia coli KP81 harboring mcr-1 plasmid. *Microb Pathog* **135**, 103646 (2019).
- 1747 184. Daly, S.M., Sturge, C.R., Felder-Scott, C.F., Geller, B.L. & Greenberg, D.E. MCR-1 Inhibition  
1748 with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to  
1749 Polymyxin in Escherichia coli. *mBio* **8** (2017).
- 1750 185. Zhou, Y. *et al.* Discovery of a potential MCR-1 inhibitor that reverses polymyxin activity  
1751 against clinical mcr-1-positive Enterobacteriaceae. *J Infect* **78**, 364-372 (2019).
- 1752 186. Guo, Y. *et al.* Honokiol Restores Polymyxin Susceptibility to MCR-1-Positive Pathogens both  
1753 In Vitro and In Vivo. *Appl Environ Microbiol* **86** (2020).
- 1754 187. Lu, N. *et al.* Isoalantolactone restores the sensitivity of gram-negative Enterobacteriaceae  
1755 carrying MCR-1 to carbapenems. *J Cell Mol Med* **24**, 2475-2483 (2020).
- 1756 188. Liu, X., Sun, X., Deng, X., Lv, X. & Wang, J. Calycosin enhances the bactericidal efficacy of  
1757 polymyxin B by inhibiting MCR-1 in vitro. *J Appl Microbiol* **129**, 532-540 (2020).
- 1758 189. Wang, Y.M., Kong, L.C., Liu, J. & Ma, H.X. Synergistic effect of eugenol with Colistin against  
1759 clinical isolated Colistin-resistant Escherichia coli strains. *Antimicrob Resist Infect Control* **7**,  
1760 17 (2018).
- 1761 190. Dos Santos, A., da Silva, M.F., de Araújo-Júnior, J.X. & da Silva-Júnior, E.F. Revealing Insights  
1762 into Natural Products Against mcr-1-Producing Bacteria. *Curr Drug Targets* (2021).
- 1763 191. Baron, S.A. & Rolain, J.M. Efflux pump inhibitor CCCP to rescue colistin susceptibility in mcr-1  
1764 plasmid-mediated colistin-resistant strains and Gram-negative bacteria. *J Antimicrob*  
1765 *Chemother* **73**, 1862-1871 (2018).
- 1766 192. Osei Sekyere, J. & Amoako, D.G. Carbonyl cyanide m-chlorophenylhydrazine (CCCP) reverses  
1767 resistance to colistin, but not to carbapenems and tigecycline in multidrug-resistant  
1768 Enterobacteriaceae. *Frontiers in microbiology* **8**, 228 (2017).
- 1769 193. Okdah, L. *et al.* New therapy from old drugs: synergistic bactericidal activity of sulfadiazine  
1770 with colistin against colistin-resistant bacteria, including plasmid-mediated colistin-resistant  
1771 mcr-1 isolates. *Int J Antimicrob Agents* **51**, 775-783 (2018).
- 1772 194. Zhang, Y. *et al.* Synergistic Effect of Colistin Combined with PFK-158 against Colistin-  
1773 Resistant Enterobacteriaceae. *Antimicrob Agents Chemother* **63** (2019).


- 1774 195. Chow, W.A., Jiang, C. & Guan, M. Anti-HIV drugs for cancer therapeutics: back to the future?  
1775 *The lancet oncology* **10**, 61-71 (2009).
- 1776 196. Elwell, L.P. *et al.* Antibacterial activity and mechanism of action of 3'-azido-3'-  
1777 deoxythymidine (BW A509U). *Antimicrobial agents and chemotherapy* **31**, 274-280 (1987).
- 1778 197. Peyclit, L., Baron, S.A., Yousfi, H. & Rolain, J.M. Zidovudine: A salvage therapy for mcr-1  
1779 plasmid-mediated colistin-resistant bacterial infections? *Int J Antimicrob Agents* **52**, 11-13  
1780 (2018).
- 1781 198. Hu, Y., Liu, Y. & Coates, A. Azidothymidine Produces Synergistic Activity in Combination with  
1782 Colistin against Antibiotic-Resistant Enterobacteriaceae. *Antimicrob Agents Chemother* **63**  
1783 (2019).
- 1784 199. Stokes, J.M. *et al.* Pentamidine sensitizes Gram-negative pathogens to antibiotics and  
1785 overcomes acquired colistin resistance. *Nature microbiology* **2**, 1-8 (2017).
- 1786 200. Barker, W.T. *et al.* Small molecule adjuvants that suppress both chromosomal and mcr-1  
1787 encoded colistin-resistance and amplify colistin efficacy in polymyxin-susceptible bacteria.  
1788 *Bioorg Med Chem* **25**, 5749-5753 (2017).
- 1789 201. Tyrrell, J.M., Aboklaish, A.F., Walsh, T.R., Vaara, T. & Vaara, M. The polymyxin derivative  
1790 NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of  
1791 *Escherichia coli*, *Klebsiella pneumoniae* and *Acinetobacter baumannii*. *Peptides* **112**, 149-153  
1792 (2019).
- 1793 202. Li, Y. *et al.* Synergistic Antimicrobial Activity of Colistin in Combination with Rifampin and  
1794 Azithromycin against *Escherichia coli* Producing MCR-1. *Antimicrob Agents Chemother* **62**  
1795 (2018).
- 1796 203. Yu, Y. *et al.* Novel partners with colistin to increase its in vivo therapeutic effectiveness and  
1797 prevent the occurrence of colistin resistance in NDM- and MCR-co-producing *Escherichia coli*  
1798 in a murine infection model. *J Antimicrob Chemother* **74**, 87-95 (2019).
- 1799 204. Zhou, Y.F. *et al.* Increased activity of colistin in combination with amikacin against  
1800 *Escherichia coli* co-producing NDM-5 and MCR-1. *J Antimicrob Chemother* **72**, 1723-1730  
1801 (2017).
- 1802 205. Zhou, Y.F. *et al.* Activity of Tigecycline or Colistin in Combination with Zidovudine against  
1803 *Escherichia coli* Harboring tet(X) and mcr-1. *Antimicrob Agents Chemother* **65** (2020).
- 1804 206. MacNair, C.R. *et al.* Overcoming mcr-1 mediated colistin resistance with colistin in  
1805 combination with other antibiotics. *Nat Commun* **9**, 458 (2018).
- 1806 207. Bulman, Z.P. *et al.* Polymyxin Combinations Combat *Escherichia coli* Harboring mcr-1 and  
1807 bla(NDM-5): Preparation for a Postantibiotic Era. *mBio* **8** (2017).
- 1808 208. Carpenter, J. *et al.* Activity of imipenem/relebactam against carbapenemase-producing  
1809 Enterobacteriaceae with high colistin resistance. *J Antimicrob Chemother* **74**, 3260-3263  
1810 (2019).
- 1811 209. Stojanoski, V. *et al.* Structure of the catalytic domain of the colistin resistance enzyme MCR-  
1812 1. *BMC biology* **14**, 1-10 (2016).
- 1813 210. Ma, G., Zhu, Y., Yu, Z., Ahmad, A. & Zhang, H. High resolution crystal structure of the  
1814 catalytic domain of MCR-1. *Scientific reports* **6**, 1-7 (2016).
- 1815
- 1816



1817


1818

1819 Figure 1. Flow diagram of literature search strategy and methodology. Out of 977 identified  
1820 records between 2015 and 2021, a total of 638 studies were included in the systematic review  
1821 whilst 550 of this were used for the epidemiological analyses.




1822

1823 Figure 2: The sources and types of Enterobacteriaceae species identified to be harbouring *mcr* genes. A) Sources reported to harbour *mcr*-  
 1824 positive Enterobacteriaceae isolates were mainly animals, humans, water, food, and environmental samples. B) Distribution of *mcr*-producing  
 1825 Enterobacteriaceae species per sample source. C) The number of reports for each *mcr*-positive Enterobacteriaceae species.



1826 Figure 3. Global distribution and total count of mcr genes. A) Total number of mcr genes reported globally. B) The distribution of mcr genes per  
 1827 country. C) Global map showing the geographical distribution of mcr genes.

1828




1829

1830 Figure 4. Global map showing the geographical distribution of antibiotic resistance genes found in all MCRPE.







1834 Figure 6. Structure of the catalytic domain of the MCR-1 protein and the five important residues required for its catalytic activity. A) The MCR-  
 1835 1's hemispherical shape composed of the  $\beta$ - $\alpha$ - $\beta$  fold made up of helices (cyan), strands (purple) and loops (salmon). Image was obtained from  
 1836 Stojanoski *et al.* (2016)<sup>209</sup>. B) A ball and stick model showing the conserved active site residues of MCR-1 consisting of Asp (D)465, Glu  
 1837 (E)246, His (H)466, His(H)395 and Thr (T)285, coordinated to the zinc ions (Zn1 and Zn2) and water molecules (W1 and W2). Image was  
 1838 obtained from Ma *et al.* (2016)<sup>210</sup>.



Total ARDs per country

Total ARDs

5236

